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 Intensity- modulated radiation therapy is a form of cancer treatment that directs high 
energy x-rays to irradiate a tumor volume. In order to minimize the damage to surround-
ing tissue the radiation is delivered from multiple angles. The selection of angles is an 
NP-hard problem and is currently done manually in most hospitals. We use previously 
evaluated treatment plans to train a machine learning model to sort potential treatment 
plans. By sorting potential treatment plans we can find better solutions while only evalu-
ating a fifth as many plans. We then construct a genetic algorithm and use our machine 
learning models to search the space of all potential treatment plans to suggest a potential 
best plan. Using the genetic algorithm we are able to find plans 2% better on average than 
the previously best known plans. 
 Proton therapy is a new form of radiation therapy. We simulated a proton therapy 
treatment center in order to optimize patient throughput and minimize patient wait time. 
We are able to schedule patients reducing wait times between 20% and 35% depending 
on patient tardiness and absenteeism. 
 Finally, we analyzed the impact of operations research on the treatment of pros-
tate cancer.  We reviewed the work that has been published in both operations research 
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In 2012, the United States spent 17.9% of its GDP on healthcare, more than any other 
nation (OBP 2014). With healthcare costs representing such a major part of the economy, 
there has been a great deal of research devoted to improving not only the treatment of 
patients, but the efficiency of healthcare delivery. The Agency for Healthcare Research 
and Quality (AHRQ) is tasked with producing evidence and guidelines to make 
healthcare safer, higher quality, more accessible, equitable, and affordable. It has repeat-
edly called for the use of operations research to increase the efficiency of healthcare de-
livery, reducing the cost, and improving the outcomes of patients (AHRQ 2011). The im-
portance of operations research in healthcare extends beyond improving the efficiency of 
healthcare systems and to the treatment of patients themselves. Increasingly sophisticated 
treatments in medicine require optimization of everything from drug plans for cancer pa-
tients to imaging of computed tomography scanners. 
In 2014, there are expected to be more than 1.6 million new cases of cancer diag-
nosed in the United States, with over half a million cancer deaths (ACS 2014). In 2009, 
the United States spent $86.6 billion on medical treatments directly related to cancer, but 
indirect mortality costs raised the total cost of cancer to an estimated $216.6 billion (ACS 
2014). The treatment of cancer represents an important part of the healthcare industry, 
with specialized doctors, hospitals, facilities, and other resources dedicated to its treat-
ment. This dissertation focuses on how operations research can be used to improve cancer 
treatment, from planning external beam radiation therapy to the efficiency of treatment 
delivery to patients. There are three parts to the research: improving the delivery of radia-
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tion to tumors in intensity-modulated radiation therapy (IMRT), scheduling patients for 
treatment at a proton therapy treatment center, and analyzing the impact of operations 
research on the treatment of prostate cancer. 
Currently, nearly two thirds of all cancer patients in the United States receive some 
form of radiotherapy (NIH 2012). IMRT is currently the most common form of external 
beam radiation therapy (Smith et al. 2011). IMRT, like all forms of radiotherapy, has side 
effects from radiation being delivered to healthy tissue surrounding the tumor and treat-
ment volume. Improving treatment plans can reduce the incident radiation to healthy tis-
sue, decreasing both acute and long term side effects. The importance of a good treatment 
plan leads to longer planning times. A good portion of the cost of IMRT is the planning 
time it takes to design each patient’s treatment plan; IMRT takes radiation oncologists 
between 30% and 88% longer than other treatment types (Van de Werf et al. 2012). The 
planning cost per patient has been estimated to be ₤484 or about $780 (Ploquin and 
Duscombe 2008). Treatment planning consists of identifying the important structures, 
deciding the beam angles, and optimizing delivery over those beam angles. The step of 
beam angle selection is currently manually performed at most hospitals with the final step 
of optimization being performed by commercial software. The manual search of beam 
angles is a time intensive iterative process. We develop a tool for sorting beam angle sets 
by potential plan quality that finds better plans while searching one fifth the number of 
plans. Such a tool could vastly decrease the time spent manually searching for angle sets 
in treatment planning. We extend this work by constructing a genetic algorithm that will 
search the space of beam angle sets for the plan it predicts will perform best. These tools 
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have the potential to improve both the treatment of the patient and to reduce the burden of 
treatment planning. 
Proton therapy is a promising new form of external beam radiation therapy. Protons 
have the ability to better pinpoint the delivery of radiation by scattering less than x-rays 
and delivering almost no radiation to the tissue behind the treatment volume. Currently, 
the size and nature of the equipment needed for proton therapy necessitates a specialized 
facility be built. The cost of such a facility and equipment runs in excess of one hundred 
million dollars. The widespread adoption of proton therapy has been greatly limited by 
this high cost. There are currently only 40 facilities worldwide. When presented with a 
treatment that is both scarce and in high demand it is important to ensure that facilities 
are designed to see as many patients as possible and that all equipment is being optimally 
used. A proton therapy treatment center is a complex system with many patients able to 
be treated in parallel, each with stochastic treatment times and multiple treatment steps. 
Furthermore, even though some steps of treatment can be done in parallel, the cyclotron 
delivering the high energy protons can supply only one treatment room at a time, mean-
ing that only one patient can receive radiation at a time. We show the throughput increase 
of having multiple treatment rooms and the diminishing returns of having too many. We 
show that when having multiple rooms relying on a common resource, scheduling pa-
tients with respect to their demand on that resource is important. We go further to analyze 
system failures and special needs of patients. We show how to maintain throughput and 
reduce patient wait times in the presence of high uncertainty in patient arrival. 
Prostate cancer is the most common form of cancer in men, with one in seven devel-
oping prostate cancer within their lifetime (SEER 2012). It has been shown that early 
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detection of prostate cancer leads to improved treatment outcomes. In an effort to detect 
prostate cancer in its early stages it has been common practice to measure the prostate 
specific antigen of men over forty. However, screening with prostate specific antigen 
leads to a large number of false positive detections, resulting in unnecessary biopsies. 
Biopsies are intrusive and carry a risk of infection. Operation researchers have simulated 
policies in order maximize the welfare gain from early detection and minimize unneces-
sary procedures. Researchers are looking for better screening alternatives including 
MRIs. The data from MRIs is complex and humans do a poor job of analyzing the images 
for prostate cancer detection. Using machine learning, however, the accuracy of detection 
can be improved well beyond that of PSA screening and human interpretation of MRI. 
Optimization techniques have also been applied to the treatment of prostate cancer 
through seed placement in brachytherapy and the decision of when to start treatment. 
From screening to post-operative monitoring, operations research has had a significant 
impact on the treatment of prostate cancer. 
 The dissertation is ordered as follows. The first section focuses on using data mining 
and genetic algorithms to improve IMRT treatment plans. The second section is on the 
optimization of beam angle selection through genetic algorithms. The third section is on 
simulating a proton therapy treatment center to test scheduling procedures. Finally, the 
fourth section is an effort to measure the impact that operations research has had on the 
treatment of prostate cancer. Each section begins with its own introduction and literature 
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 The beam angle optimization problem for Intensity-Modulate Radiation Therapy 
(IMRT) has been well studied. Previous research has focused on developing optimization 
approaches to obtain a single high quality angle set for each patient. In this research, we 
propose a population-based method to aid the beam angle selection process with the goal 
of significantly improving the efficiency of the process while identifying high-quality 
angles. We used a database of 2,700 IMRT treatment plans for 10 patients with locally 
advanced head and neck cancer. We used machine learning to rank beam angle sets to 
determine those most likely to be of high quality. Logistic regression, neural network, 
and k-nearest neighbor algorithms were used with different parameters and feature sets. 
The ranking algorithms are able to find better angle sets by evaluating just three plans 




Over the last 10 years, intensity-modulated radiation therapy (IMRT) has become 
one of the dominant forms of external beam radiation therapy. IMRT replaced 3D con-
formal radiation therapy for treating many types of cancer because it is better able to 
spare the surrounding healthy tissue while maintaining the prescription dose to the tumor. 
This increased precision in delivering radiation is particularly important in tumors sur-
rounded by vulnerable tissue, such as cancer in an advanced stage. This increased preci-
sion comes with increased complexity, making the IMRT planning problem NP-hard 
(Saher and Sultan 2010). Current IMRT planning procedures have yet to use the vast 
amount of information collected from the optimizing of treatment plans for the tens of 
thousands of patients who undergo IMRT every year. 
An oncologist and a medical physicist collaborate on producing plans for the 
IMRT planning problem (we refer to them as the planners). There are three primary stag-
es in solving the planning problem. During the first stage, organs at risk (OARs) and the 
tumor are delineated on the CT scan (X-ray computed tomography). The tumor and tissue 
immediately adjacent to it are referred to as the planning target volume (PTV). The PTV 
and nodal volumes are assigned varying levels of radiation to ensure that the malignant 
cells are destroyed. An isocenter is selected and the radiation source (a linear accelerator 
in the case of X-ray IMRT) is pivoted on a gantry arm around the isocenter. Typically, 
the isocenter is chosen to be the center of mass of the tumor and varies from patient to 
patient. The isocenter may vary, to a lesser degree, over the course of treatment. 
The second stage of the planning process involves the selection of beam angles to 
deliver the radiation relative to the patient’s anatomy. First, the planners must decide how 
many beam angles to use. Research has shown that while more beam angles might spread 
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out the radiation, ensuring no individual organ receives too high a dose, there are dimin-
ishing returns for too many angles (Mohan and Ling 1995; Narayanan et al. 2012; Söder-
ström and Brahme 1995; Stein et al. 1997). In addition, there are practical limitations. For 
example, each additional angle increases the amount of time needed to deliver the radia-
tion, which can cause complications for very sick patients. Wu et al. (2010) suggested 
that the dosimetric quality of plans is dependent on the number of beam apertures used. 
No matter how many angles are used, a minimum number of aperatures is required to 
ensure adequate plan quality. 
After deciding on the number of angles to use, the values of the angles are chosen. 
Angle selection is usually done manually, despite research showing that intelligent beam 
angle selection can further reduce radiation to the OARs (Aleman et al. 2008, 2009; Pu-
gachev et al. 2001). Much of the literature on optimizing beam angles focuses on beam 
view methods (Cho et al. 1999; Goitein et al. 1983; Myrianthopoulos et al. 1992; Puga-
chev and Xing 2001a, 2001b, 2002). These methods evaluate one beam plan at regular 
intervals and create a vector of radiation delivered to both the tumor and the OARs. A set 
of angles is then constructed based on the performance of the individual beam plans. 
Methods of optimizing using the beam view method include simulated annealing (Ale-
man et al. 2008), mixed integer programming (D’Souza et al. 2004; Lee et al. 2006; Lim 
et al. 2008; Wang et al. 2003), genetic algorithms (Li et al. 2004; Schreibmann et al. 
2004), clustering (Bangert and Oelfke 2010) and heuristic approaches (Aleman et al. 
2008; Bertsimas et al. 2013; Cao et al. 2012; Craft 2007; D’Souza et al. 2008; Lim and 
Cao 2012; Misic et al. 2010; Potrebko et al. 2007).  
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Artificial neural networks have been applied to the beam angle selection problem. 
In Rowbottom, et al. (1999), neural networks were trained with a single angle set for each 
patient. The angle set was generated using a heuristic that was previously shown to pro-
duce good angle sets (Rowbottom et al. 1998). By using only a single angle set for each 
patient, the information gained from the multiple sets that are typically evaluated during 
planning is lost. The authors used the neural network to generate an angle set given input 
parameters, instead of evaluating a beam angle set.  
In the third stage, after the beam angles have been selected, beam intensity pro-
files are computed for each angle. The objective function for this stage ensures that the 
tumor receives the prescription dose, while minimizing the radiation to the surrounding 
tissue. There are many ways to model these objectives. Linear and quadratic forms are 
used to penalize delivering radiation to healthy tissue or delivering an insufficient dose of 
radiation to the treatment area. The penalty weights for the PTV and OARs are specified 
by the planners for a patient. The planners often adjust the penalty score equation as a 
way of modifying computer optimized plans without changing beam angles. From each 
angle, the intensity profile of the beam is divided into pixels or beamlets as variables to 
be optimized, which gives a flexible control of radiation dose delivered to a patient. This 
level of control is especially useful for concave and oddly shaped tumors. A comprehen-
sive discussion of the IMRT planning problem can be found in four review papers (Bort-
feld 2006; Hunt and Burman 2003; Romeijn and Dempsey 2008; Webb 2003). 
In practice, for a given beam angle set, the beam intensity profiles are optimized 
using commercial software. Typically, the selection of beam angles is constructed manu-
ally and is based on the experience of the planners designing the plan. The optimization 
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of beam intensity profiles for a given set of beam angles is computationally expensive, 
taking up to 30 minutes per plan using the planning software. In current clinical practice, 
IMRT treatment planning is an iterative process. After the computationally expensive 
plan generation process is performed by clinicians, treatment plans are presented to phy-
sicians for approval. Frequently, physicians would like the clinicians to improve the plan 
quality by balancing the doses to different structures. This iterative process to achieve the 
final plan is even more time-consuming. The goal of this paper is to develop a model for 
sorting potential beam angle sets in order to identify those that are high quality, so that 
the number of plan evaluations can be limited during the computationally expensive third 
step of optimization. With the help of our method, top ranked plans that have different 
dose distributions to different OARs (but have similar overall quality) could provide phy-
sicians with more flexibility in plan selection and eliminate the time-consuming iterative 
process. A patient population-based method utilizing data mining tools is proposed in 
order to identify quality beam angles for a new incoming patient. Using the results of 
previously evaluated beam angle sets to aid in the selection of which sets to evaluate al-
lows us to use the thousands of hours of computer processing that have already been 
spent optimizing plans for cancer patients. The purpose of this new tool is not to find the 
best of all possible plans, but to take advantage of prior knowledge to identify the most 
promising angle sets for full evaluation. It can be used along with any beam angle opti-
mizers in order to speed up the process. In Section 2, we discuss the data used for the de-
velopment of the data mining models. In Section 3, we fine tune the model parameters 
and present the results of each model. In Section 4, we provide concluding remarks and 




Our population is built from 2709 evaluated treatment plans of 10 locally ad-
vanced head and neck cancer patients. Each plan has seven coplanar beam angles. Each 
patient has between 252 and 282 evaluated plans, 11 of which are rotations of seven 
evenly spaced angles rounded to the nearest five degrees. The remainder of the plans are 
randomly generated. The patients have different isocenters and tumor geometries, but all 
share the same set of OARs. The OARs includes the right and left parotid (salivary 
glands), oral mucosa, spinal cord, and brainstem. The treatment targets include primary 
PTV, high risk nodal volumes (high risk PTV), and low risk nodal volumes (low risk 
PTV). 
2.2.1 Penalty Score to evaluate plan quality 
The penalty score formula, which is widely used in the literature (Cao et al. 2012; 
Misic et al. 2010; Romeijin and Dempsey 2012), is consistent across the 10 patients. 
Scores are weighted sums of violations of the desired dose values for both the OARs and 
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where αi is the penalty associated with delivering excess radiation to OAR and PTV in 
the score calculation, which reflects the priority of satisfying the corresponding constraint 
of the OAR or the PTV during the planning process. Similarly, i  is the penalty associat-
ed with failing to deliver sufficient radiation to the PTV. The specified desired dose val-
ue, measured in Grays (Gy), for each OAR and PTV (di) is listed in Table 2-1 (note that 
multiple values can be specified for each OAR and PTV). Ai represents the actual dose 
achieved by the treatment plan at a percentage volume of the OAR or PTV. For the 
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OARs, the goal is to deliver as little radiation as possible. The most sensitive tissues, such 
as the spinal cord and brain stem, have a limit as to the maximum amount of absorbed 
dose that can be received by any part of the tissue. For these OARs, the di is measured in 
maximum Grays received. Before calculating the penalty score, the treatment plan is 
normalized so that the primary PTV receives the prescription dose (70 Gy) to ensure that 
enough dose is being delivered to the tumor. In Figure 2-1, we show a cross section of 
one patient demonstrating the difficulty of the cases considered. The three treatment tar-
gets were surrounded by OARs, and the spinal cord was sitting within the concavity of 
the targets.  
Constraint di αi, βi 
Less than 66% of the left parotid receiving 26 Gy 3 
Less than 33% of the left parotid receiving 32 Gy 3 
Less than 66% of the right parotid receiving 26 Gy 3 
Less than 33% of the right parotid receiving 32 Gy 3 
Less than 90% of the oral mucosa receiving 30 Gy 8 
Less than 30% of the oral mucosa receiving 40 Gy 8 
Maximum spinal cord dose  45 Gy 15 
Maximum brain stem dose 54 Gy 15 
More than 95% of the low-risk PTV receiving 54 Gy 6 
Less than 5% of the low-risk PTV receiving 59.4 Gy 6 
More than 95% of the high-risk PTV receiving 59.4 Gy 6 
Less than 5% of the high-risk PTV receiving 70 Gy 6 






Figure 2-1: A cross section of a CT for a patient depicting the PTV and OARs. 
 
2.2.2 Angle Set Evaluation 
The associated beam intensity profiles were optimized using P
3
 IMRT, part of the 
Pinnacle
3
® Planning system by Phillips (2013). P
3
 IMRT optimizes the dosage to the 
specified OAR and PTV using a sequential quadratic programming algorithm for solving 
general nonlinear optimization problems. There are 1,000 to 10,000 variables, and the 
process of optimizing the intensity profiles for a set of beam angles can take between 5 
and 30 minutes. Each angle set had seven coplanar angles which is consistent with previ-
ous research (Bortfeld and Schlegel 1993; Liu et al. 2006; Takamiya et al. 2007) that has 
explored the trade-offs involved in using more beam angles. Also, in accordance with 
practice, no two beam angles were spaced less than 30 degrees apart or opposite between 
170 and 190 degrees of another.  
2.2.3 Models 
Three different methods were compared: linear regression, neural networks 
(Haykin 1994), and k-nearest neighbor (Aha 1991). Each method used fully evaluated 
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beam angle sets with penalty score as observations, and was tested by predicting the pen-
alty score of beam angle sets on which it had not been trained.  
Linear regression allows for an interpretable model with no predetermined model 
parameters. The linear regression models were constructed using the R software package 
(R Core Team 2013). Both the linear regression and neural network models used the pa-
tient ID, normalized angle sets, normalized product of each pair of angles, and normal-
ized cube of each angle as feature sets. Patient ID identifies the patient whose penalty 
score was evaluated from the beam angle set. The patient ID allows for patient fixed ef-
fects to be captured using nine dummy variables that allow for the identification of the 10 
patients. 
Neural networks require several model parameters to be specified prior to train-
ing, including activation functions, network topology, and a learning algorithm. A hyper-
bolic tangent activation function (a common activation function) is used for all nodes in 
the network. A neural network has an input layer, hidden layer, and output layer. We 
have to decide on the number of hidden layers and the number of neurons in the hidden 
layers. Too many neurons in the hidden layer will result in overfitting and long computa-
tion times. Too few neurons will result in underfitting. The network has one hidden layer 
with a number of nodes equal to one more than half the size of the feature set. The hidden 
layer is fully connected to both the input and output layers. Backpropagation is the learn-
ing algorithm. There are several parameters associated with backpropagation including a 
learning parameter and momentum. We set the learning parameter value at 0.01 and mo-
mentum at 0.90. MATLAB release 2012b and the Neural Networks Toolbox (MATLAB 
2012) were used to construct and test the neural network models.  
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Finally, k-nearest neighbor is an instance-based learner that uses the Euclidean 
distance between the angle set being evaluated and the angle sets in the training set to 
determine the k nearest instances. The penalty score is then estimated, giving more 
weight to the penalty scores of the closer instances. The k-nearest neighbor algorithm 
requires no training time. Weka 3.6 (Hall et al. 2009) was used to run the k-nearest 
neighbor algorithm with k set to seven (based on predictive performance on test set) and 
the distance weight set to the inverse of the Euclidean distance between angle sets. The k-
nearest neighbor algorithm used only the patient ID and normalized angle set as features. 
2.3 Results 
 Models were generated using 5-fold cross-validation on the 2,709 beam angle sets. 
Four folds are used as training data, with the fifth fold being withheld for testing. The 
data mining algorithms were trained to predict the penalty score for each beam angle set. 
For each patient, the plans were then sorted by their predicted penalty score and this rank-
ing was compared to the actual ordering of the plans. For each 5-fold cross-validation, 
this process results in 50 ordered lists (5 folds each with 10 patients). Each list has be-
tween 50 and 56 beam angle plans for a specific patient. We used 5-fold cross-validation 
rather than the more common 10-fold cross-validation to allow for a larger test set. This 
results in an average list of 54 plans for each of the 10 patients to be sorted (10-fold 
cross-validation would have an average list size of only 27 plans). By using fewer folds, 
we double the size of the test set for each run, but reduce the size of the training set by 
less than 12%. 
 The model predictions correlate well with the actual penalty scores. The correlation 
coefficients are 0.85 for the linear regression model, 0.83 for the neural network model, 
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and 0.90 for the k-nearest neighbor model. To estimate time savings and performance 
improvements, however, we need to know how well the models predict the order of the 
lists they are sorting. In Table 2-2, we see that all the data mining methods outperform 
the baseline of taking the same number of elements from an unsorted list. 
 The probability of finding the best of the potential plans in a list is more than 
doubled at all levels by using simple machine learning methods. Evaluating the top three 
ranked plans by k-nearest neighbor produces better results, on average, than evaluating 15 
plans from an unsorted list. If we were to evaluate only six plans, the average rank of the 
best plan found using a k-nearest neighbor sorted list is less than a quarter of that found 
by randomly evaluating six plans. The best plan is found 54% of the time, almost five 
times as often when evaluating six random plans. A top three plan is found 86% of the 
time (almost three times as often as evaluating six random plans) and a top five plan is 









rank of best 
plan found  






of finding a 
top 3 plan 
 
Probability 
of finding a 
top 5 plan 
 
Rank of bottom 
10th percentile 
of best plan 
found 
(out of 54) 
Baseline      
 
Random 3 13.8 5.6 16.0 25.7 30 
Random 6 7.9 11.1 30.3 45.9 18 
Random 9 5.5 16.7 42.8 61.4 13 
Random 12 4.2 22.2 53.7 73.1 10 
Random 15 3.4 27.8 63.2 81.8 8 
 
Linear Re-
gression      
 
Top 3 7.4 14 34 46 17 
Top 6 3.8 22 56 80 8 
Top 9 3.2 26 62 86 6 
Top 12 2.5 38 74 94 4 
Top 15 2.0 50 88 98 4 
 
Neural Net-
work      
 
Top 3 7.1 16 40 52 15 
Top 6 3.7 32 64 84 10 
Top 9 2.9 38 74 90 5 
Top 12 2.4 50 78 94 5 
Top 15 2.0 56 86 98 4 
 
k-Nearest 
Neighbor      
 
Top 3 3.0 34 76 92 5 
Top 6 2.2 54 86 94 4 
Top 9 2.0 62 90 94 3 
Top 12 1.9 68 92 94 3 
Top 15 1.6 70 96 98 2 
Table 2-2: Performance of linear regression, neural network, and k-nearest neighbor algo-
rithms over a 5-fold cross-validation resulting in 50 ordered lists with an average of 54 
elements per list. This is compared with the baseline performance of a randomly ordered 




 In Figures 2-2 to 2-5, we see that k-nearest neighbor strictly dominates both linear 
regression and neural network models, both of which dominate a randomly sorted list. 
However, k-nearest neighbor is more sensitive to the number of dimensions used (Beyer 
et al. 1999). If the dimensionality is too high, the performance declines. This property 
might limit the ability of k-nearest neighbor models to explicitly handle large numbers of 
patient variables found in larger databases (our models use dummy variables for each 
patient). Neural network and linear regression models both can effectively use a larger 
feature set than the k-nearest neighbor, so long as the number of instances is sufficiently 
large. 
 In Figure 2-5, we see that, by searching just six plans using k-nearest neighbor, on 
average, the penalty score of the best plan found is less than five percent above that for 
the best plan in the list. This result compared to a penalty score over 20% above that for 
the best plan using an unsorted list. Even searching 15 plans with an unsorted list still 
yields a penalty score that is over 10% above that for the best plan in the list. Given that 
the ultimate goal of any sorting or optimization technique is to improve the quality of the 
plans being used, we see that, by sorting the list prior to evaluation, we can evaluate far 
fewer plans and still find high-quality plans. 
 The penalty score of the top ranked plan from each of the 50 lists of plans averages 
between 4% and 5% less than the plan used in clinical experience for both linear regres-
sion and neural networks. The k-nearest neighbor algorithm achieves a 17% reduction. 
Similarly, when comparing the penalty score of the average top ranked plan in each list 
with the results of commercial software, we find an 11% reduction for the linear regres-





Figure 2-2: The average rank of the best plan found by evaluating a fixed number of plans 
from a list of 54 elements. 
 
 
Figure 2-3: The probability of finding the best plan in a list of 54 elements by evaluating 
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Figure 2-4: The probability of finding one of the three best plans in a list of 54 elements 
by evaluating a fixed number of plans. 
 
 
Figure 2-5: The percent difference between the penalty score of the actual best plan of a 
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Figure 2-6: A comparison of the DVHs for one patient comparing plans based on clinical 
experience (red), commercial software (blue), and a sample run using the top ranked plan 
from a list sorted using linear regression. The OARs and PTVs are separated for presenta-
tion purposes. 
The overall beam angle quality obtained using either clinical experience, com-
mercial software, or the top plan from a list sorted using data mining is demonstrated us-
ing the dose-volume histograms (DVHs) in Figure 2-6. The DVH presents the fractional 
volume of each OAR or PTV that receives at least a certain absorbed dose (in Gy) of ra-
diation. All three approaches provided the required coverage for PTVs (primary, high risk 
(HR) and low risk (LR)). However, the data mining approach obtained the most uniform 
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dose for all three PTVs. The bigger differences were achieved for spinal cord, oral muco-
sa, and brain stem. At least a 10% improvement (reduction in maximum dose) was 
achieved by the data mining approach for sparing of the spinal cord compared to the oth-
er methods. A 15% improvement of oral mucosa sparing was achieved as well. We can 
see that data mining successfully identified beam angle sets that yielded significantly im-
proved treatment plans relative to clinical plans and commercially implemented optimiza-
tion techniques. Appendix 2-1 gives an example of an alternate plan (with slight changes 
to the beam angles) developed using k-nearest neighbor that improves upon the plan 
based on clinical experience with respect to penalty score. 
In Table 2-3, we compare the performance of the three data mining algorithms 
(linear regression, neural network, k-nearest neighbor) to the plans produced by clinical 
experience, the Eclipse treatment planning system (Varian 2013), and a nested partitions 
optimization algorithm (D’Souza et al. 2008). The optimization algorithm has been 
benchmarked against other methods found in the literature (Lim et al. 2012). The 
achieved dose (in Gy) at each constraint setting level is listed in the table, which were 
averaged for the 10 patients. The plans for the data mining methods are based on the best 
of the top three ranked plans in the fold, from 5-fold cross validation, where the test set 
contained the best-known plan for that patient. The linear regression model reduced the 
penalty from 90% of the oral mucosa receiving more than 30 Gy by 12% compared to 
clinical and more than 15% compared to the Eclipse system. Each data mining method 
reduced the delivery to the brain stem compared to the clinical and Eclipse plans, reduc-
ing the penalty by 6% to 9%. The top-ranked plans from our data mining methods per-

















More than 95% of 
the high-risk PTV 
receiving 59.4 Gy 
61.6 61.6 60.4 61.1 60.7 60.6 
Less than 5% of 
the high-risk PTV 
receiving 70.0 Gy 
69.1 69.3 68.0 68.2 68.0 68.6 
More than 95% of 
the low-risk PTV 
receiving 54.0 Gy 
56.5 56.2 55.0 55.4 54.9 55.2 
Less than 5% of 
the low-risk PTV 
receiving 59.4 Gy 




49.3 51.0 48.7 48.1 47.9 48.5 
Less than 66% of 
the left parotid 
receiving 26.0 Gy 
17.0 18.2 17.4 17.8 17.4 17.5 
Less than 33% of 
the left parotid 
receiving 32.0 Gy 
42.2 42.1 40.0 42.0 40.0 41.1 
Less than 66% of 
the right parotid 
receiving 26.0 Gy 
18.6 18.7 18.4 18.3 18.3 19.0 
Less than 33% of 
the right parotid 
receiving 32.0 Gy 




38.2 38.1 35.1 34.6 35.8 36.3 
Less than 90% of 
the oral mucosa 
receiving 30.0 Gy 
17.5 18.2 15.4 17.0 16.9 16.5 
Less than 30% of 
the oral mucosa 
receiving 40.0 Gy 
45.7 45.2 43.1 43.6 43.0 43.6 
Table 2-3: The actual dose (in Gy, averaged over the 10 patients) achieved at each con-
straint setting level for plans produced by clinical experience, the Eclipse system, linear 




the optimizer was consistently ranked among the top five plans of at least one data min-
ing method. 
As the length of the list being sorted grows, we cannot say for certain how per-
formance will scale. Due to the approximate limit of 270 plans per patient that we have to 
work with, we cannot test the performance on lists of arbitrary lengths. Once trained, 
both linear regression and neural network models can be run quickly to evaluate many 
potential treatment plans. To evaluate each new plan simply requires a few matrix multi-
plications. The k-nearest neighbor algorithm requires no training time, which would be an 
advantage when selecting a training set that most closely resembles a patient. 
2.4 Discussion 
 This research has the potential to use the vast amount of information that is gathered 
during the IMRT planning process. Every plan that was evaluated for the thousands of 
patients undergoing treatment each year could potentially be used. As the population da-
tabase grows, it will become possible to include more patient specific variables such as 
tumor geometry and location, information that models trained on a small number of pa-
tients cannot utilize. 
 Alternatively, a subset of patients with similar conditions could be selected as the 
training set for each new patient, thereby eliminating the need of adding new variables to 
the model. A repository of tumor shapes and anatomies of patients for each disease site, 
along with all plans calculated during a patient’s treatment planning phase, could serve as 
the training set for new patients with the same disease site. Although there are databases 
of medical imaging of tumors that are currently available, they do not include treatment 
information. When a new patient considers treatment, we could, with our tools, identify 
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potential high-quality beam angle sets. Treatment information could easily be attached to 
such a database and previous tumors could be simulated for treatment plans as well. 
Research (Dink et al. 2012) has shown that using multiple beam angle sets over a 
series of treatments has the potential to improve outcomes. Unlike previous work that 
focused on finding a single best angle set, by sorting, we can find multiple good angle 
sets; these would allow for a greater distribution of angles to be used with time-varying 
plans. Appendix 2-2 gives an example of two plans (obtained from linear regression) with 
disparate angle sets that have a similar penalty score and spare different OARs. This also 
gives the physician more flexibility to choose a treatment plan based on the trade-offs 
between the OARs. 
Our research has similar implications for use with adaptive treatment planning. 
Current treatment plans are static throughout the treatment process. Adaptive treatment 
seeks to anticipate response to treatment and adjust accordingly. Given that the tumor 
will likely change slowly over the course of the treatment, plans developed for preceding 
stages could serve as training instances for screening future sets and distinct angle sets 
could be found to better distribute the radiation. 
In future work, we will incorporate patient specific anatomical features (Chanya-
navich et al. 2011; Magome et al. 2013) to improve the prediction of the penalty score 
and ranking accuracy. After improving the accuracy, we will incorporate the data mining 
models within an optimization method to identify the optimal angle set with limited qual-
ity evaluations. 
In conclusion, we have shown that previously evaluated beam angle sets can be 
used to help identify the potential of new angle sets. Sorting plans shows great promise in 
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speeding the search for good angle sets by helping find plans with low penalty scores 
first. Future models might recommend how many plans should be evaluated based on the 
relative performance of the new plans to the existing training plans. This would allow for 
fewer plans to be evaluated if their predicted penalty score was higher than the plans that 





Figure 2-7: A comparison of the DVHs for one patient comparing plans based on clinical 
experience (black) and a sample run using the top ranked plan from a list sorted using k-
nearest neighbor (blue). The OARs and PTVs are separated for presentation purposes. 
The k-nearest neighbor model was able to identify a plan similar to the one used 
in clinical practice, that differed by more than five degrees on only two angles, that im-
proved the penalty score by 24%. In Figure 2-7, we see that while the clinical plan deliv-
ers less radiation to the oral mucosa, the k-nearest neighbor plan reduces radiation deliv-
ered to the left parotid and delivers a high dose to a smaller fraction of the brain stem. 





The top two plans from a list sorted using a linear regression model were com-
pared. The plans penalty score differed by less than 1%, but four of the angles used dif-
fered by at least 15 degrees. Figure 2-8 shows similar dosing for the brain stem, left and 
right parotid, and PTV. One plan spares the spinal cord, the other spares the oral mucosa. 
Having multiple plans with the same penalty score allows for plans to be compared using 
objectives not included in the penalty score.  
 
 
Figure 2-8: A comparison of the DVHs for one patient comparing two top ranked plans 
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Abstract: Developing treatment plans for intensity-modulated radiation therapy (IMRT) 
involves first selecting beam angles and then optimizing the delivery of radiation from 
those angles. Optimizing the delivery of radiation for a set of beam angles is a time inten-
sive process and finding the beam angles from which to best deliver the radiation is an 
NP-hard problem. We use machine learning to construct models to quickly estimate the 
quality of optimized plans for new angle sets. These models are used as objective/fitness 
functions in a genetic algorithm (GA) that searches the space of feasible beam angle sets. 
Our GA quickly finds solutions for new patients based on the models trained on previous-
ly evaluated treatment plans for other patients. The solutions found are more than 2% 







 Intensity-modulated radiation therapy (IMRT) is a form of external beam radiation 
therapy that uses x-rays to irradiate a tumor. Since the radiation also affects the healthy 
tissue surrounding the tumor, the x-rays are projected from multiple angles with the tu-
mor at the center. A linear accelerator is used to generate the x-rays and is mounted on a 
gantry arm that can be rotated to deliver the radiation from multiple angles. Using multi-
ple angles allows the radiation to be delivered in multiple doses, distributing the dose to 
healthy tissue to minimize damage, while delivering a concentrated lethal dose to cancer-
ous tissue. A multi-leaf collimator is used to control the precise delivery of radiation. The 
collimator can be moved while the radiation is being delivered, blocking the x-rays for a 
period of time to control the exposure. This further minimizes damage to healthy tissue, 
by controlling the amount of radiation being delivered to each pixel from each angle to 
ensure lower dosage to areas with more sensitive tissue. 
 Constructing a treatment plan for a patient is a three stage process. In the first stage, 
the patient is imaged so that all important tissue in the treatment area can be identified. 
An oncologist identifies the tumor and tissue at risk of cancer, the planned treatment vol-
ume (PTV), and prescribes radiation levels for these areas that will kill the cancerous tis-
sue. Next, the organs at risk (OAR) of damage from radiation are assigned thresholds of 
radiation, below which, damage from radiation is considered acceptable. Plans are evalu-
ated using an objective function that penalizes plans for delivering either too little radia-
tion to the PTV or too much radiation to the OAR. 
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 The second stage involves selecting angles from which to deliver the radiation. Using 
multiple angles allows for the radiation to be distributed and these angles can be chosen 
to avoid delivering radiation to more sensitive tissue. The beam angle selection problem 
has been shown to be NP-hard (Saher and Sultan 2010). Using more angles has diminish-
ing returns and leads to longer treatment times. The selection of angles for treatment is 
still primarily done manually by trial and error. 
 The third stage of the planning process is to decide the precise way in which to deliv-
er the radiation from each angle. The PTV creates a cross section when viewed from each 
angle. The cross section is divided into pixels. Using multi-leaf collimators, the delivery 
of radiation can be precisely controlled to each pixel of the cross section. Given the large 
number of pixels and the interaction between their deliveries, the optimization of this 
planning phase is done using commercial optimization software. The software can take 
up to 20 minutes to optimize the delivery of radiation for an angle set. For a more in 
depth discussion of IMRT and the treatment planning process, literature reviews are 
available (Bortfeld 2006; Hunt and Burman 2003; Romeijn and Dempsey 2008; Webb 
2003). 
 IMRT is currently the most popular form of external beam radiation therapy in the 
United States. Each year thousands of treatment plans are developed for patients under-
going IMRT. These treatment plans have the potential to form the basis of a database that 
can be used to guide future treatment plan construction. Previous work (Price et al. 2014) 
has shown that using machine learning to sort potential beam angle sets could aid treat-
ment planners in deciding which angle sets to examine. However, sorting or evaluating 
all possible angle sets is infeasible. An efficient way to search the space of angle sets is 
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needed in order to generate good solutions. Dias et al. (2014) use neural networks trained 
for individual patients to serve as the fitness function for a beam angle search procedure, 
but such a method requires that new neural networks be trained for each patient and mul-
tiple beam angle sets be evaluated for these patients to train the neural networks. Our 
work aims to use a genetic algorithm (GA) to search the space of potential beam angle 
sets for the set of angles, which when radiation delivery from these angles has been opti-
mized, will minimize the objective function value, thus minimizing damage to OAR and 
delivering an appropriate level of radiation to the PTV. Instead of optimizing the radia-
tion delivery for each angle set, we use machine learning trained on previous patients to 
develop models that predict the objective function value of optimized beam angle sets. 
Our GA is able to improve upon the best known solutions by more than 2%.  
 The paper is organized as follows. Section 2 explores the methods used by the ma-
chine learning models and Section 3 describes the details of the GA. Section 4 presents 
the results of the plans identified by the GA using the different fitness functions from the 
machine learning algorithms. Section 5 provides conclusions. 
3.2 Methodology 
  This section covers the steps taken in constructing the GA. First, we discuss the 
penalty function used to optimize the plans. Our work is applied to head and neck cancer 
patients and a customized penalty function is used. Next, we examine the data used to 
train the machine learning algorithms. For this data set, the beam angle sets are evaluated 
for patients using commercial software. This data is then used to make models to predict 
the penalty score using machine learning. Finally, the machine learning models are part 
of a genetic algorithm used to search the space of beam angles. 
32 
 
3.2.1    Penalty Function 
We use a linear penalty score formula commonly used in the literature (Cao et al. 
2012; Misic et al. 2010; Romeijin and Dempsey 2012). The penalty score evaluates the 
relative quality of the treatment plans based on how they deviate from a series of OAR 
and PTV target values. The penalty score is a weighted sum of violations from the de-
sired dose values for both the OARs and the PTVs. Better plans have fewer violations 
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where αi  and i  are the weights associated with each OAR and PTV in the score calcula-
tion. The weights reflect the seriousness of violating the constraint of the OAR or the 
PTV during the planning process, with more important structures receiving higher 
weights. Table 3-1 lists the desired dose values (di), measured in Grays (Gy), for each 
OAR and PTV. OARs more sensitive to radiation will have lower desired dose levels, 
while the PTV at highest risk will have larger desired dose levels. There can also be mul-
tiple constraints each OAR or PTV. Ai represents the actual dose achieved by the treat-
ment plan at a percentage volume of the OAR or PTV. For the OARs, the goal is to de-
liver as little radiation as possible. The most sensitive tissues, such as the spinal cord and 
brain stem, have a limit on the maximum amount of absorbed dose that can be received. 
For these OARs, the di is measured in maximum Grays received. The treatment plan is 
normalized so that the primary PTV receives the prescription dose (70 Gy) prior to calcu-







Constraint di αi, βi 
Less than 66% of the left parotid receiving 26 Gy 3 
Less than 33% of the left parotid receiving 32 Gy 3 
Less than 66% of the right parotid receiving 26 Gy 3 
Less than 33% of the right parotid receiving 32 Gy 3 
Less than 90% of the oral mucosa receiving 30 Gy 8 
Less than 30% of the oral mucosa receiving 40 Gy 8 
Maximum spinal cord dose  45 Gy 15 
Maximum brain stem dose 54 Gy 15 
More than 95% of the low-risk PTV receiving 54 Gy 6 
Less than 5% of the low-risk PTV receiving 59.4 Gy 6 
More than 95% of the high-risk PTV receiving 59.4 Gy 6 
Less than 5% of the high-risk PTV receiving 70 Gy 6 
Table 3-1: Summary of dose and dose-volume constraints for locally advanced head and 
neck cases  
 
3.2.2    Data 
The associated beam intensity profiles were optimized using P
3
 IMRT, part of the 
Pinnacle
3
® Planning system by Phillips (2013). P
3
 IMRT optimizes the dosage to the 
specified OAR and PTV using a sequential quadratic programming algorithm for solving 
general nonlinear optimization problems. There are 1,000 to 10,000 variables, and the 
process of optimizing the intensity profiles for a set of beam angles can take between 5 
and 30 minutes. Each angle set had seven coplanar angles which is consistent with previ-
ous research (Bortfeld and Schlegel 1993; Liu et al. 2006; Takamiya et al. 2007) that has 
explored the trade-offs involved in using more beam angles. Also, in accordance with 
practice, no two beam angles were spaced less than 30 degrees apart or opposite (between 
170 and 190 degrees of one another).  
 We use two populations to train our machine learning algorithms. The first popu-
lation is a set of treatment plans that deliver radiation from five beam angles. The set 
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consists of 1,740 treatment plans evaluated for 10 locally advanced head and neck cancer 
patients. A total of 174 plans are evaluated for each patient with 160 of them being ran-
domly generated and 14 representing equally spaced angle sets. The average penalty 
score of the plans is 303, while the average of the best plan known for each patient is 179. 
Five angle plans take less time to deliver the radiation than seven angle plans. This allows 
for faster treatment times for patients, meaning less time immobilized for their daily 
treatments. 
 Our second population is built from 2,709 evaluated treatment plans of 10 locally ad-
vanced head and neck cancer patients. Each plan has seven coplanar beam angles. Each 
patient has between 252 and 282 evaluated plans, 11 of which are rotations of seven 
evenly spaced angles rounded to the nearest five degrees. The remainder of the plans are 
randomly generated. The average penalty score of the plans is 266, while the average of 
the best plan known for each patient is 163. These scores reflect the fact that seven beam 
plans can better spread the radiation across healthy tissue, allowing for better penalty 
scores than the five beam plans, about 10% on average. The patients have different iso-
centers and tumor geometries, but all share the same set of OARs. The OARs includes 
the right and left parotid (salivary glands), oral mucosa, spinal cord, and brainstem. The 
treatment targets include primary PTV, high risk nodal volumes (high risk PTV), and low 
risk nodal volumes (low risk PTV). 
3.2.3    Machine Learning 
 The penalty function for evaluating plan quality is based on the levels of radiation 
being delivered to the OAR and PTV of the patient. The radiation being delivered is 
based on the optimal plan arrived at by P
3
 IMRT planning software, which was optimized 
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over a set of beam angles. It is reasonable to assume that arbitrarily small changes in 
beam angle will bound the magnitude of the changes in the penalty function. We assume 
that the penalty score of the optimized treatment plan for a patient is a continuous func-
tion of the beam angles used in the plan. To estimate the shape of this function, we use 
machine learning and regression methods based on previously optimized beam angle sets 
for each patient. To begin, we use a variety of basic techniques and then use combina-
tions of these techniques to improve performance. Techniques used include regression, 
neural networks, radial basis functions, and k-nearest neighbors. 
 Assuming that the penalty function is a continuous function of the beam angles im-
plies that the function can be approximated with any desired level of accuracy by a suffi-
ciently high order polynomial. Unfortunately, the number of coefficients that needs to be 
estimated for higher dimension polynomials proliferate quickly with an increase in the 
dimensionality. Starting with a feature set that includes the beam angles, first order inter-
action terms, the square of beam angles, and the cubes, stepwise regression is used to se-
lect features with high predictive value. Four stepwise regressions are run; forward re-
gression starting with no features and adding those with high predictive value, backward 
stepwise regression starting with all features and removing those with little predictive 
value, and stepwise regression with both forward and backward movements beginning 
from the empty and full feature sets. 
 Neural networks are a form of machine learning that can be trained to identify com-
plex, non-linear patterns. A neural network is defined by its topology, activation function, 
and learning algorithm. We use a three layer system composed of input, hidden, and out-
put layers. Each layer is fully connected with the next. An inverse arctangent activation 
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function is used, having been shown to work well with the resilient propagation (RPROP) 
learning algorithm (Riedmiller 1993). RPROP is an adaptive form of back-propagation 
that adjusts learning parameters in response to the error function during the training 
phase. After it has been trained, a neural network can be run quite quickly. 
 Radial basis function networks are a special type of neural networks that use radial 
basis functions as activation functions. The basis function centers are chosen as a random 
sample of the training set. Radial basis function networks are a popular method for func-
tion interpolation. 
 Finally, k-nearest neighbor is an instance based method that requires no training. The 
k closest neighbors in the training set to a new instance are found and a weighted sum of 
their penalty score is used to predict the penalty score of the new instance. While no 
training is required, it requires that the distance to each observation in the training set is 
calculated for each new instance. Based on the performance of using different numbers of 
neighbors, we use seven neighbors weighted by the inverse distance to the new instance. 
Nearest neighbor is a popular method for multidimensional interpolation, but can be slow 
as the training set grows.    
 A shortcoming of using an interpolation method like k-Nearest Neighbor (kNN) 
to predict the value of a new beam angle set is that the predicted value of any beam angle 
set is bounded by the maximum and minimum values in the training set. Therefore, when 
using kNN to search the space of all beam angle sets, the predicted optimum would be an 
extreme point from the training set. Extrapolation methods, on the other hand, are vulner-
able to extreme predictions, well outside anything in the training set, especially when 
searching a large space. For example, regressions with polynomial terms of second or 
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third order can have extreme values at the boundary of the space. This can result in pre-
dicted values which are several standard deviations from anything seen in the training set. 
 To balance the shortcomings of the two methods, we propose a method of com-
bining predictions that gives greater weight to interpolation methods when extrapolation 
methods have values many standard deviations from the norm of the training set. Let μ be 
the mean of the training set and σ be the standard deviation. Letting Φ(x) represent the 
inverse function of the normal distribution. Then for k(a) being the kNN prediction for an 








Note that when the predicted value of the extrapolation is too many standard devia-
tions from the norm, the more stable interpolation term dominates the extreme extrapola-
tion term. Appendix 3-1 justifies the use of the inverse normal distribution. 
 There are multiple methods for combining machine learning models. Methods that 
use a simple or arbitrary rule decided a priori, such as weighting the models equally or 
weighting based on predictive accuracy in the training set, can use a single training set 
without overestimating the predictive value. If, however, one wishes to learn how best to 
combine multiple machine learning models, it is important to use two training sets. The 
first training set is used to train each of the basic model methods (in our case kNN, RBF, 
Linear Regression, Neural Networks). The second training set is used to learn how to 
combine the predictions of each of the machine learning methods to better predict the 
penalty score. This is particularly important to avoid overfitting. We use multiple meth-
ods to combine methods including the previously mentioned probabilistic method, equal 
weight, and proportional weight.  
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3.2.4    Tumor Geometry 
 An important piece of information that our earlier data mining methods (Price et 
al. 2014) did not include is tumor geometry. When mining plans are performed on a sin-
gle patient, tumor geometry is unimportant because the geometry information is constant 
across all the beam angle sets. Since we are working with a small number of patients, but 
a large number of evaluated plans for each patient, we used fixed effects. Fixed effects 
capture that the geometry is the same within a patient, but different between patients. 
Fixed effects, however, have limited use in capturing any similarities or differences be-
tween patients that might affect beam angle performance and improve the machine learn-
ing models predictive performance on new patients. Figure 3-1 shows how the geometry 
as seen from each beam angle is different, this allows for different geometric data to be 
















Figure 3-1.Picture illustrating a beam’s eye view of patient specific geometry from two angles.  
The tumor (red) and lymph nodes (yellow) are part of the PTV, while the brain stem (dark blue), 
spinal cord (green), oral mucosa (light blue), and parotids (beige and olive) are the OARs. The 
exact size, shape, and location of each patients OARs and PTV will be unique. 
39 
 
  The ten patients in our data set have locally advanced stage III and IV tumors. 
These tumors have grown quite large and are irregularly shaped. The number of variables 
to fully encode the information on the tumors size, shape, and location relative to the 
OARs exceeds the number of patients we have in our data set. Because there are more 
geometry variables than patients, attempts to explicitly describe the tumor will fail to 
have statistical meaning. We developed a method for encoding the geometric data from 
the beam angles used for each patient. 
  To integrate some geometric data into our angle sets, we use a method described 
in D'Souza et al. (2004). For each of the 72 beam angles that can be a part of a beam an-
gle set, a fixed dose of 2 Gy of radiation was simulated firing at the entire area of the 
beam's eye-view projection of the PTV. The radiation delivered to each of the OAR is 
recorded and the mean organ dose (MOD) is calculated. In this way, coarse geometric 
information is included by capturing the overlap of the projections of the OAR and PTV 
when viewed from each angle. The MODs, however, fail to capture all the geometric in-
formation and present a worst case scenario, since the radiation delivery from each beam 
angle can be modulated to further reduce the radiation received. The beam angle sets can 
now be viewed as a set of MOD vectors that hint at how each angle in the set will con-
tribute to the final penalty score. For example Figure 3-1 shows the tumor in red, when 
delivering a fixed dose of radiation from the angle depicted on the left, the unobstructed 
PTV (red and yellow) to the right parotid (olive) receives a MOD of 69.7. Delivering the 




3.2.4    Results on Training Set  
 Table 3-2 presents the results of the basic models using ten-fold cross validation. 
The correlation coefficient is the most important metric for purposes of searching the 
space for optimal values as keeping the relative order of the solutions is necessary for 
identifying the proper minimum. The other metrics hint at how far the model differs from 
the actual value on average (mean absolute error, MAE, and relative absolute error, RAE) 
or weighting large variations more (root mean square error, RMSE, and relative root 
square error, RRSE). All methods are dominated by k-nearest neighbors, with linear re-
gression coming in second. Neural networks perform similarly to linear regression in 
maintaining correlation but have larger MAE and RMSE values, implying that neural 




Coefficient MAE RMSE RAE RRSE 
Linear Regres-
sion 0.8468 39.6027 55.7426 46.6201 54.728 
 
kNN 0.8978 31.0624 45.0694 36.5665 44.249 
 
Neural Network 0.8285 44.6507 64.5706 52.1623 62.7801 
Radial Basis 
Function 0.7962 46.9434 66.082 54.8407 64.2496 
 
Table 3-2: The correlation coefficient, mean absolute error (MAE), root mean square er-
ror (RMSE), relative absolute error (RAE), and relative root square error (RRSE) of the 




 Table 3-3 shows the correlation between the error terms of the basic models. The 
error terms are positively correlated which limits the potential of strictly additive meth-
ods. As we can see in Table 3-4, the performance of the hybrid methods offer marginal 
improvements for most metrics. Our proposed probability blended method has the best 
performance, outperforming the simple additive methods and the best of the basic mod-
els. 
 
RBF NN LR kNN 
RBF 1 0.39815 0.67373 0.5572 
NN 0.39815 1 0.54376 0.5924 
LR 0.67373 0.54376 1 0.6654 
kNN 0.5572 0.5924 0.6654 1 
 
Table 3-3: The correlation of the error terms of the different methods. The positive corre-
lation of the errors implies that simply additive methods will not necessarily outperform 






Coefficient MAE RMSE RAE RRSE 
Equal Weights 0.8894 32.3872 47.6961 37.5603 45.428 
Proportionally 
Weighted 0.8938 31.4654 45.9395 36.9264 44.747 
Probability 
Weighting  0.9098 28.3979 42.9551 33.1753 41.764 
 
Table 3-4: The correlation coefficient, mean absolute error (MAE), root mean square er-
ror (RMSE), relative absolute error (RAE), and relative root square error (RRSE) of the 
combined methods from ten-fold cross validation. 
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3.2.5    Geometric Results 
 Using the geometric data described in Section 2.3.1 may encourage methods that 
will better adapt to new patients, requiring no plans to be evaluated prior to searching 
with the GA. Table 3-5 shows that using only aggregate MOD data, without using fixed 
effects for patients or angle data, we are able to perform comparably to models that use 
fixed effects and several angle based variables. Since no fixed effects are used for pa-
tients, the expected accuracy on new patients should be the same as the results from the 
10-fold cross validation. Expanding the feature set to include angle variables and interac-
tion terms further improves the accuracy as seen in Table 3-6. Linear regression, radial 
basis functions, and neural networks all have similar results with k-nearest neighbor out 
performing all other methods. The k-nearest neighbor algorithm performed best when run 





Coefficient MAE RMSE RAE RRSE 
Linear Regres-
sion 0.6588 59.0513 77.3239 68.9852 75.1797 
 
kNN 0.8775 33.5294 49.5358 39.1701 48.1622 
 
Neural Network 0.7768 50.3131 65.5260 58.7773 63.7089 
Radial Basis 
Function 0.8307 41.1039 57.2227 48.0188 55.6359 
Table 3-5: The correlation coefficient, mean absolute error (MAE), root mean square er-
ror (RMSE), relative absolute error (RAE), and relative root square error (RRSE) of the 






Coefficient MAE RMSE RAE RRSE 
Linear Regres-
sion 0.8447 39.5234 55.0196 46.1724 53.4939 
 
kNN 0.9124 28.0211 42.3556 32.7351 41.1807 
 
Neural Network 0.8402 41.4411 56.3871 48.4128 54.8235 
Radial Basis 
Function 0.8428 39.5441 55.3516 46.1966 53.8168 
Table 3-6: The correlation coefficient, mean absolute error (MAE), root mean square er-
ror (RMSE), relative absolute error (RAE), and relative root square error (RRSE) of the 
basic methods using full feature set from ten-fold cross validation. 
3.3 Genetic Algorithm  
 Genetic algorithms are a meta-heuristic used to search for optimal solutions to 
combinatorial optimization problems. Genetic algorithms maintain a population of poten-
tial solutions and generate new solutions over successive generations in order to search 
for an optimal solution. Solutions to the optimization problem are represented as chromo-
somes. We use the ordered beam angle set as a chromosome. The fitness function is used 
to judge the quality of each chromosome; it determines which chromosomes are passed 
from one generation to the next. To generate new solutions, mutations, crossovers, and 
other search techniques can be employed. Finally, stopping criteria are set to determine 
when to terminate the search. 
3.3.1    Population Size and Stopping Criteria  
 The running time of a genetic algorithm is proportional to the population of solu-
tions that are evaluated each generation and the number of generations. Small populations 
have a higher likelihood of crossover between any two chromosomes in the population 
and quickly discard low performing solutions. Small populations, however, have the po-
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tential of being stuck at locally optimum solutions if the population becomes too homog-
enous. Larger populations are slower to become homogenous. They also may store an 
excessive numbers of solutions with little promise of leading to the optimal solution. To 
test which would be most appropriate to search the space of beam angles, the perfor-
mance of combinations of population size and generations were used to evaluate ideal 
population size and stopping criteria. Table 3-7 shows the population size and generation 
counts used to determine the stopping criteria. 
 A polynomial objective function with multiple local optimums was used to cali-
brate a set of parameters used for all the machine learning objective functions in the ge-
netic algorithm. While running very quickly, compared to the other machine learning fit-
ness functions, the polynomial objective function can be used to calibrate the GA to 
search the space. Figure 3-2 shows the average convergence of the different population 
sizes to the optimal solution. For each population size, the GA was run 1,000 times and 
the results were averaged. Every run of the GA converged to the optimal solution of the 
polynomial. As expected, larger population sizes converge more quickly. Figure 3-3 
shows the generation in which the optimal solution was found for each of the 1,000 runs. 
This information can be used to determine how many runs would have failed to find the 
optimal solution had the termination criteria been set lower. The goal is to determine the 
population size that minimizes the total number of chromosomes evaluated by calculating 











Table 3-7: All experiments evaluated a total of approximately 20,000 chromosomes and 







Figure 3-2: Plot of percentage of best solution found by nth generation. Each population 


































Figure 3-3: Histogram of which generation the best plan was found during. If the total 
number of generations was set to less than any of these numbers, then all runs in which 
the best generation was found to the right would not find the optimal solution. 
 
Figure 3-4: Percent of runs that would converge to best solution if the run were truncated 


























































Figure 3-5: Percent of runs that would find optimal solution if the run were set to termi-






















































10 263 5,260 641 12,820 
20 129 5,160 277 11,080 
50 76 7,600 158 15,800 
100 54 10,800 84 16,800 
 
Table 3-8: The total runtime of the Genetic Algorithm (GA) is proportional to the number 
of solutions evaluated. A population size of 20 had a minimum maximum number of so-
lutions evaluated. 
 In addition to stopping after a fixed number of generations, many GAs have a 
secondary stopping criteria based on when the best solution found has been the same for 
many generations. This is used to terminate in case the search is stuck in a local optimum. 
To determine where to set this stopping criteria, we calculated the length of every streak 
of the same best solution, prior to finding the actual best solution. If the stopping criteria 
was set too low, the optimal solution would not be found as the search would have been 
terminated prematurely.  
 
 
Figure 3-6: Plot of the length of consecutive generations with same best solution, prior to 























given length, then all runs with streaks longer would have not found the optimal solution. 
Zero was excluded from the figure as the number of cases that new best solutions were 
found consecutively was an order of magnitude greater due to local search. 
3.3.2 Mutation, Crossover, and Local Search 
A mutation function takes a single angle set and mutates it to return a new valid 
angle set. A crossover function takes two different angle sets and returns a single new 
valid angle set that somehow combines the two. Mutations help to maintain population 
diversity, while crossovers help to blend solutions to combine the best features of each. 
Table 3-9 shows the mutation and crossover functions that were used by our GA. The 
second chromosome for crossover functions can either be chosen randomly with uniform 
probability from the population, selected randomly with probability proportional to the 
fitness function value, or the chromosome with the best known fitness function value. We 
used a roulette system which favored higher ranked chromosomes for crossover. 
 
Title Description of Function 
Mutation 1 Replaces a random angle from an angle set with a new angle to create a 
new valid angle set 
Mutation 2 Each angle is shifted by either -5, 0, or 5 degrees 
Mutation 3 Rotates all angles by the same amount 
Mutation 4 Replaces a random angle with the angle 180 degrees from that angle 
Crossover 1 Replaces a random angle from the first chromosome with one from the 
second chromosome 
Crossover 2 Replace a random angle from the first chromosome with one between it 
and the nearest angle from the second chromosome (including end 
points)  
Crossover 3 Shifts all ordered angles in chromosome one in the direction of the same 
ordered angle in chromosome two 
Table 3-9: A list of the five mutation and three crossover functions tried as part of our 





 Step 1:  Randomly select a beam angle from the beam angle set. 
 Step 2: Replace with angle from the set of angles valid with respect to other an-
gles in set. 
 Step 3: Order new angle set from smallest to largest. 
 
Mutation 2: 
 Step 1: Randomly add -5, 0, or 5 to each angle. 
 Step 2: If the resulting beam angle set is valid accept, else return to Step 1. 
 
Mutation 3: 
 Step 1: Randomly select an angle at 5 degree intervals from 5 to 355 and shift all 
angles in the angle set by this amount. 
 Step 2: Take all angles Mod 360 and order new angle set from smallest to largest. 
 
Mutation 4: 
 Step 1: Randomly order the beam angle set into a list. 
  Step 2: Replace the next angle in the list with the angle 180 from the original an-
gle. If the angle set is invalid replace with original set, and repeat Step 2. 
 Step 3: Take all angles Mod 360 and order new angle set from smallest to largest. 
 
Crossover 1: 
 Step 1: Randomly order Chromosome A and Chromosome B. 
 Step 2: Replace first angle in Chromosome A with the first from Chromosome B, 
if valid accept, else take the next from Chromosome B. If no valid replace-
ments for first angle in Chromosome A found, then repeat process for next 
angle in Chromosome A. 
 Step 3: Order new angle set from smallest to largest. 
 
Crossover 2: 
 Step 1: Choose a random angle from Chromosome A. 
  Step 2: Create a set of angles valid with the remaining angles in Chromosome A 
between the chosen angle and the corresponding angle from Chromosome B. 
Replace angle with randomly selected angle from the list. 
 
Crossover 3: 
 Step 1: Pair each angle in Chromosomes A and B. Randomly order pairs. 
  Step 2: For each angle pair; If corresponding angle in Chromosome B is larger, 
then add 5 degrees to angle from Chromosome A. If the corresponding angle 
in Chromosome B is smaller, then subtract 5 degrees to the angle from Chro-
mosome A. If the resulting angle set is valid, accept change, otherwise reject. 
 
Table 3-10: Outline of algorithms 
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 In addition to mutation and crossover functions, a local search was implemented. 
The local search was performed each time a new best solution was found, examining all 
angle sets within 5 degrees of the new best solution. 
 Prior to optimizing the probability of each mutation and crossover function, we 
examined which mutation, crossover, and search procedures were contributing to finding 
the best solution. Starting with the random construction of chromosomes in the first gen-
eration, every new solution generated records the methods used to generate its parent and 
adds the method used to generate it. Each mutation, crossover, and local search is coded 
with a unique letter. Figure 3-7 compares the distribution of crossovers and mutations 
used to generate the best solutions for population sizes of 10 and 100 chromosomes. For a 
population size of 100, an average of 19.7 steps were used to generate the optimal solu-
tion compared to 34.5 steps for a population size of 10.  
 
Figure 3-7: Corresponding to the methods in Table 3-9 shows the average number of mu-
tations, crossovers, and local searches involved in finding the optimal solution for popu-























 Larger populations are typically associated with lower crossover and mutation 
probabilities and smaller populations with higher probabilities (Srinivas and Patnaik 
1994). This corresponds with the need to keep small populations diverse in order to pre-
vent getting stuck at a local optimum. Experiments were done to determine the best com-
bination of mutation and crossover functions to use with each fitness functions. Each mu-
tation and crossover function has a probability of occurring and parameter optimization 
was used to choose the best parameters for each fitness function. The steps of the parame-
ter optimization are listed in Table 3-11. The performance of each set of parameters in 
step 2 will be determined by averaging the results of 1,000 runs of the GA.  
 
Step 1 Initialize with all mutations and crossovers having an equal probability  
Step 2 Compare the performance of raising the probability of each mutation or cross-
over by the step size, while reducing the probability of all others by step size / 
(number of mutation/crossover -1) 
Step 3 If performance improves,  then choose the step that results in maximum im-
provement and repeat step 2,  
Else If the step size has reached stopping criteria, then end  
        Else reduce step size by half and repeat step 2 
 
Table 3-11: List of steps when optimizing mutation/crossover parameters for GA 
3.4 Results 
The genetic algorithm was run 100 times for each of the machine learning models, for 
each of the patients. Each unique solution was then evaluated using the Pinnacle Planning 
software. The average results were calculated by weighting the penalty score by the num-
ber of times the genetic algorithm returned each solution. Table 3-12 shows the results of 
the different machine learning methods normalized to k-nearest neighbor, which returns 
the best known solution for each patient from the observation set. The entire set of obser-




Method Average Best Average 
Runtime 
Linear Regression 117.4 117.4 9.4s 
Radial Basis Function 110.3 102.2 14.5s 
Neural Network 105.8 98.3 13.2s 
k-nearest neighbor 100.0 100.0 328.7s 
Equal Weights 99.6 97.5 342.3s 
Probability Weighted 97.9 96.1 356.8s 
Table 3-12. Performance of GA results with respect to the previously best known plan. 
Lower scores are better. Runtimes of the GA on an Intel® Core ™ i5 CPU with 2.4 GHz 
and 6 GB of RAM. Bold indicates the best performance in each column.  
As seen in Table 3-12, the basic methods did not tend to return solutions that were better 
than the known solutions. By using combinations of the basic machine learning methods, 
we were able to improve upon the best known solution. Some methods such as linear 
regression and k-nearest neighbor converged to a single solution in all runs of the GA. 
Other methods had less consistent results, sometimes finding better solutions and 
othertimes failing to match the best known solution. Table 3-12 also shows the runtime of 
the different methods in finding a solution. As can be seen, the methods that do not call 
on k-nearest neighbor have a significantly faster runtime. To improve the runtime of 
methods that call on k-nearest neighbor, we could limit calls to evaluate k-nearest 
neighbor to when the other machine learning models predicted an angle set that was of 
very high quality. 
3.5 Conclusions  
The improvement in the treatment plan quality by 2% over the best known plan implies 
that using models developed by machine learning to evaluate potential treatment plans is 
a viable method for beam angle selection. The quality of the predictions can be expected 
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to improve as the number of plans and patients in the training set increases. For methods 
that include k-nearest neighbor, this might result in unacceptably long search times when 
using the full training set. Given that similarities in tumor geometry and location are in-
ferred based on the MOD of the 72 beam angles, identifying patients with similar tumors 
is simply a matter of checking the distance between vectors of MOD instead of a com-
plex image analysis problem.  Using a subset of patients with similar tumor geometries 
would likely speed the search and further improve the results. Methods that incorporate 
multiple machine learning methods performed the best in our research, but as the set of 







































Figure 3-9: Plot matching the sample quantile values with those of a normal distribution. The 
figure shows the deviations from normal distirubtion of the penalty scores for the seven beam 
plans. Note that the  quantiles closely resemble normal for plan with lower than median penalty 
score. This implies that good plans resemble the first half of the normal distribution, while the 








Figure 3-11: Plot matching the sample quantile values with those of a normal distri-
bution. The figure shows the deviations from normal distribution of the penalty scores for 










 Figures 3-8 to 3-11 show that the distribution of penalty scores follows a right 
skewed normal distribution. The close fit of the distribution for values below the median 








is valid for use for low penalty score methods. Given that we are searching for plans 
that have penalty scores at the left tail of the distribution, the formula should be valid for 
competitive plans. The right skew of the distribution implies that there will be an over-
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 Proton therapy is a form of radiation therapy with the potential to reduce the amount 
of radiation exposure received by healthy tissue during the course of cancer treatment. 
This leads fewer acute and long-term side effects. Due to the costs involved in construct-
ing a proton therapy facility, there are only 10 facilities operating in the United States 
currently. These facilities need to treat as many patients as possible, while minimizing the 
time a patient spends waiting in the system. There are stochastic elements in the treat-
ment time, and planners need to take into account all relevant patient information in con-
structing a schedule. Important information that is known prior to scheduling includes the 
design of the treatment plan, residential status of the patient, and special needs of the pa-
tient. We simulate the operations of a proton therapy treatment center in order to generate 






 The Maryland Proton Treatment Center involves an investment of more than $200 
million to build a proton therapy treatment center that includes imaging equipment, offic-
es, and accommodations for patients (Roylance 2010). This large initial investment is 
what makes proton therapy so expensive for patients.  Due to the large initial investment, 
only 10 proton therapy treatment centers are operating in the United States currently 
(there are more than 10,000 linear accelerators used for x-ray intensity modulated radia-
tion therapy (IMRT) worldwide) with eight more in development (National Association 
for Proton Therapy 2013). A cyclotron is needed to accelerate protons to the speed re-
quired for treatment. It is a much larger piece of equipment than the linear accelerators 
used for photons in x-ray IMRT. Typically, a new facility is built to house the equipment 
needed for PT, whereas linear accelerators can be installed in existing hospitals. When 
building an entirely new facility, there are few limitations that are imposed on placing the 
equipment. A wide array of layouts and configurations of the equipment can be consid-
ered. Our goal is to optimize the layout for patient throughput, while maintaining reason-
able patient wait times. First, we need to determine how many gantry and imaging rooms 
are needed to ensure the cyclotron is used at full capacity. Second, we need to determine 
if the imaging rooms are fully connected to the gantry rooms or are there dedicated imag-
ing rooms. Third, given a layout that can utilize the cyclotron at or near capacity, we need 
to determine whether or not the patient arrival rate affects patient wait time and machine 
idle time. Finally, we need to examine the effect of patient tardiness and absenteeism on 
patient wait time and machine idle time. 
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 Patients undergoing proton therapy typically receive treatment five days a week for 
four to five weeks. Daily treatments take less than an hour and do not typically require 
anesthesia or other drugs that might affect a patient’s daily routine. Some patients will 
come from out of town for treatment and will have an extended stay. The small number 
of side effects allows for local patients to continue working while receiving treatment. 
Tardiness of outpatients has been observed in other settings (Alexopoulos et al. 2008) and 
is likely to occur among local patients. 
 In Figure 4-1, we show the flow of patients through the treatment center. Patients en-
ter the center and proceed to a waiting room where they wait for an available imaging 
room to begin treatment. Each daily treatment begins with a detailed imaging process to 
ensure the radiation is delivered to the precise treatment location. The biggest advantage 
of PT over IMRT is its ability to deliver a precise, highly concentrated dose of radiation. 
When accurately delivered, this results in less damage to the surrounding tissue and fewer 
side effects (Lundkvist et al. 2005). Accurate delivery is important because the higher 
radiation levels delivered by PT will easily destroy healthy tissue if accidentally irradiat-
ed (Schulz-Ertner and Tsujii 2007). Errors in imaging and patient immobilization have 
been cited as the cause of adverse reactions in the treatment of prostate cancer (Wroe, 
Rosenfeld, and Schulte 2007). In remote positioning, the patient is positioned in the im-
aging room and moves between rooms immobilized on a transporter. Upon entering the 
imaging room, the patient rests on the transporter and is immobilized and prepared for 
imaging. A computer tomography (CT) scanner is used to identify the planned treatment 
volume. Marks are made on the patient’s skin that will later help align the proton beam. 
The transporter with the patient is undocked from the CT scanner and moved to the gan-
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try room. The transporter is docked with the gantry arm and aligned in preparation for 
treatment. The patient receives radiation from one, two, or three different beam angles. 
For each beam angle, the radiation is delivered over the cross section of the planned 
treatment volume from that angle and divided into pixels. Each pixel receives a different 
dose of radiation. After the patient has been treated, technicians dismount the patient 
from the transporter and return the transporter to the imaging room. The patient is dis-
charged.  
 
Figure 4-1: Patient flow through a PT treatment center. Patients may have to wait be-
tween rooms. 
 There is very little published research on the scheduling and operations of PT treat-
ment centers. The Paul Scherrer Institute (PSI) in Switzerland was the first to use remote 
patient positioning for proton therapy. The process used by PSI is described in the paper 
by Bolsi et al. (2008). The authors showed that remote positioning provided fast patient 
transport and maintained high accuracy in the delivery of radiation. The benefits of re-
mote patient positioning when compared to traditional in-room positioning in PT treat-
ment centers was examined in a follow-up paper based on simulations using data gath-
ered from PSI (Fava et al. 2012). The authors ran simulations to compare patient 
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throughput of remote and in-room positioning with a variety of transport speeds, imaging 
times, and beam delivery times. The authors imposed a strict three-minute waiting time 
limit for patients, so that a limited range of gantry and imaging room configurations were 
considered. 
 In this paper, we compare the performance of dedicating an imaging room to each 
gantry room to fully connecting imaging rooms to gantry rooms. We examine the rela-
tionship of patient inter-arrival rate (total daily throughput) to patient wait time  and ma-
chine idle time. 
4.2 Simulation Model 
We built our model using NetLogo 5.0.3, a specialized agent-based simulation language 
(Wilensky 1999).  We chose NetLogo because it has all the capabilities that we require 
for this project and it is available to the public at no charge. In addition, using an agent-
based modeling language, such as NetLogo, will allow the simulation to be extended to 
include more complex patient, facility, and personnel interactions in future versions of 
our model. Currently only patient and facility (i.e., the cyclotron) agents are implement-
ed. Our model is run in discrete time with each tick representing five seconds. The treat-
ment times that are used in our model come from an analysis of a PT treatment center 
using remote positioning due to Fava et al. (2012). The treatment steps and times are 
shown in Table 4-1. Treatment times for each step are drawn from a symmetric triangular 
distribution and are rounded to the nearest tick. A symmetric triangular distribution is 
used to ensure that all times are bounded and positive. A symmetric triangular distribu-







Table 4-1: Mean time and standard deviation of the steps used in our model based on 
treatment sessions at the Paul Scherrer Institute (taken from Fava et al. (2012)). Step 2 
occurs in the CT scanning room while steps 4 through 10 take place in the gantry room. 
Beam delivery time based on manufacturer estimate. 
 In our simulation runs, a patient is randomly assigned a treatment plan with one, two, 
or three beam angles. For each patient, we record the amount of time waiting for entry 
into the imaging room and gantry room, and the amount of time waiting in the gantry 
room for the cyclotron. 
 The waiting room is where a patient enters the system at the scheduled arrival time. If 
all imaging rooms are in use, then a count is recorded of the time a patient spends in the 
waiting room. Otherwise, the patient passes immediately into an available imaging room. 
For experiments that include a distribution of arrival times about a patient’s scheduled 
appointment time, the wait time only includes time spent in the waiting room after the 
time of the scheduled appointment. 
Treatment Steps Mean 
Time 
(minutes) 
Range of Values 
[min, max] 
(1)   Patient enters the facility                                                                   0.00 [0.00] 
(2)   Imaging                                                    16.83 [8.50, 25.17] 
(3)   Move to gantry room 1.33 [1.33] 
(4)   Prepare for beam angles 6.67 [4.25, 9.08] 
(5)   First beam angle 1.25 [1.25] 
(6)   Move gantry arm 1.50 [1.50] 
(7)   Second beam angle 1.25 [1.25] 
(8)   Move gantry arm 1.50 [1.50] 
(9)   Third beam angle 1.25 [1.25] 
(10) Discharge patient and reset gantry room 4.83 [2.83, 6.83] 
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 Each imaging room can service only one patient at a time. The patient undergoes a 
series of procedures in the imaging room. These procedures are the same for each patient 
and each room. The amount of time taken for each step of the imaging process is drawn 
from a triangular distribution and uses the means and ranges listed in Table 4-1. For each 
imaging room, we record the time spent without a patient and the time spent with a pa-
tient waiting to transfer to a gantry room. 
 Each gantry room can service only one patient at a time. Radiation is delivered to 
each patient from one, two, or three different beam angles. In addition to the time taken 
to deliver the radiation from each angle, the gantry arm must be repositioned between 
each angle. The time spent to rotate the gantry arm and treat a beam angle is fixed at 90 
and 75 seconds, respectively, as these are purely automated steps. Treatment steps 4 and 
10 are performed in the gantry room and their times are drawn from triangular distribu-
tions. For each beam angle, the gantry room must determine if the cyclotron is ready to 
fire. For each room, we record the time spent empty and the time spent waiting for the 
cyclotron. 
 The cyclotron provides protons for the gantry rooms. In addition to the 75 seconds a 
cyclotron spends treating a beam angle, it must wait an additional 45 seconds before ser-
vicing a different gantry room. When several rooms have requests for protons, they are 
serviced first come, first served. For the cyclotron, we record total time spent idle and 
time spent with one or more outstanding requests for protons. 
 All runs of our model have one cyclotron. The number of gantry and imaging rooms 
varies from run to run. Patients arrive at regular intervals that vary from run to run. Imag-
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ing rooms were either dedicated to specific gantry rooms or were fully connected to all 
gantry rooms as shown in Figure 4-2. 
 
Figure 4-2: Configurations with dedicated imaging rooms (top) versus shared imaging 
rooms (bottom). 
4.3 Simulation Results 
 In order to determine the steady-state throughput, we ran simulations for 250,000 
ticks (about 340 hours of simulated operation), where the first 50,000 ticks were treated 
as a burn-in period. The simulations ran with patients arriving whenever an imaging room 
became available (this could be thought of as an infinite waiting room scenario). The re-
sulting throughput (expressed in patients per hour) provides an upper bound on through-
put for one to seven gantry rooms because there is always a patient ready to enter the 
gantry room.  In Figure 4-3, we see a 26% increase in throughput by adding a fourth 
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room, another 14% for a fifth room, but only 6% for a sixth room. With six rooms, the 
cyclotron is idle less than 2% of the time. Therefore, additional rooms can do little to in-
crease throughput and only result in longer patient wait times in the gantry room. 
 
 
Figure 4-3: Average patients per hour, excess time in a gantry room (minutes), and per-
cent of time that the cyclotron is idle as a function of the number of gantry rooms for a 
one cyclotron system. In this system, there is always a patient ready to enter an available 
gantry room. 
 
 The average excess time spent in the gantry room is an aggregate measure. We need 
to look at the distribution of wait times. From Figure 4-3, for four gantry rooms, there is 
an average of 2.46 minutes of excess time spent in the gantry room at maximum capacity. 
In Figure 4-4, we see that, under these same conditions, many patients still spend more 
than three minutes waiting for the cyclotron in the gantry room. As the number of gantry 
rooms increases, both the mean and variance of wait time increase. The increased 
variance makes it difficult to bring maximum wait time below three minutes, since the 




Figure 4-4: Percentage of patients experiencing various wait times for 10,000 patients. 
 
 The remaining experiments are performed on 100 days of simulated facility 
performance. Including daily startup effects is more realistic than using only steady-state 
behavior. In Table 4-2, we see that, by decreasing the arrival rate (given by patients per 
hour), we can reduce the wait times of patients. For example, by increasing the time 
between patient arrivals in a four gantry room and five imaging room system from 300 
seconds (12.00 patients per hour) to 320 seconds (11.25 patients per hour), we reduce the 
average total wait time by over 55%. In Figure 4-5, we see that, even when operating 
below maximum throughput and having an average wait time of 2.72 minutes, 47% of the 
patients have wait times longer than three minutes in the gantry room.  
 There are long wait times in the gantry room; in contrast, 80% of patients spend 
no time waiting in the waiting room, 56% spend no time waiting in the imaging room, 
and 1.2% spend no time waiting in the gantry room. The multi-modal nature of the time 
spent in the gantry room (see Figure 4-5) is a result of the different treatment plans (one, 
two, or three beam angles) for patients. We constructed Figure 4-5 with patients arriving 



















Number of Rooms Number of Patients Time Spent (minutes) 
Gantry Imaging Per Hour Per Day Waiting Imaging Gantry Total 
4 4 11.25 157.50 0.51 1.33 1.87 3.71 
4 5 11.25 157.50 0.03 1.42 1.83 3.28 
4 5 12.00 168.00 1.39 3.78 2.21 7.38 
5 5 12.00 168.00 0.00 0.40 2.63 3.03 
5 5 13.33 186.67 0.68 1.72 3.33 5.73 
 
Table 4-2: The average wait time by room for six combinations of arrival rates, gantry 
rooms, and imaging rooms for 100 simulated days of operation.  
 
 
Figure 4-5: Percent of patients experiencing wait times for a system with five gantry 
rooms and five imaging rooms using an arrival rate of 13.33 patients per hour (given in 
Table 4-2) for 100 simulated days. 
When scheduling patients, it would be important to distribute patients of each type 
throughout the day, because more beam angles means a longer time in the gantry room on 
average. For five imaging and gantry rooms, by simply alternating among the three plan 
























the gantry room by 37 seconds. The percent of patients spending more than three minutes 
in the gantry room falls from 47% to 39%. The multi-modal nature of the distribution has 
not changed in Figure 4-6, but the long tail from consecutive three beam plans (which 
take more time in the gantry room) now falls off much more quickly. 
 It is important to determine the sensitivity of waiting times to real-world factors such 
as patient tardiness and absenteeism. Both of these factors play important roles in sched-
uling outpatient procedures (Liu, Ziya, and Kulkarni 2010). The arrival times for patients 
not staying at the facility are modeled by a symmetric triangular distribution centered on 
the patient’s scheduled arrival time and is 18 minutes in either direction. The 18-minute 
triangular distribution is an approximation of the fitted distribution found in the empirical 
study by Liu, Ziya, and Kulkarni (2010). Absenteeism rates are set at 5% for patients not 
staying at the facility. Half of the patients are estimated to stay at the facility and thus 
would be far less likely to be absent or tardy. 
 In Figure 4-7, we see that the distribution of waiting times look very similar. Despite 
seeing 2.5% fewer patients due to absenteeism, the wait times are longer in each part of 
the system when patient tardiness is included in the model. There is a 10% increase in 
waiting time in the gantry room and a 27% increase in the total time spent waiting in the 
system. To address the problem of patient tardiness, we note that patients staying at the 
treatment center will have greater flexibility in scheduling their treatment time. Patients 
not staying at the treatment center could be scheduled first, allowing them to choose 
times when they would be less likely to arrive late. Given that many patients actually ar-
rive early for their appointments in outpatient settings (Liu, Ziya, and Kulkarni 2010), a 




Figure 4-6: Percent of patients experiencing wait times for a system with five gantry 
rooms and five imaging rooms with an arrival rate of 13.33 patients per hour for 100 
simulated days of patients with alternating treatment plans. 
 
Figure 4-7: Percent of patients experiencing wait times for a system with five gantry 
rooms and five imaging rooms with an arrival rate of 13.33 patients per hour for 100 














































4.4 Extending the Simulation 
We extend the work of Price et al. (2013) by adding patients with different treatment time 
distributions, late arrival distributions, and waiting room prioritization. The treatment 
times are based on the estimates from Fava et al. (2012) and manufacturer estimates have 
been updated reducing the beam delivery time and gantry arm rotation time. Treatment 
times are modeled using a symmetric triangular distribution with mean time and range 
given in Table 4-3. A symmetric triangular distribution has a single peak and wide range 
of values while ensuring that all times are bounded and positive. 
 
Table 4-3: Mean time and range of values for the steps used in our model based on treat-
ment sessions at the Paul Scherrer Institute (taken from Fava et al. (2012)). Step 2 occurs 
in the CT scanning room while steps 4 through 10 take place in the gantry room. The de-
livery time and rotation between each of the beam angles is based on manufacturer esti-
mate. 
 
Patients have three basic characteristics: inpatient status, treatment plan, and sched-
uled arrival time. Inpatient status determines a patient’s probability of late arrival or ab-
senteeism. We assume that an inpatient arrives on time and needs to be transported by 
Treatment Steps Mean Time 
(minutes) 
Range of Values 
[min, max] 
(1)   Patient enters the facility                                                                   0.00 [0.00] 
(2)   Imaging                                                    16.83 [8.50, 25.17] 
(3)   Move to gantry room 1.33 [1.33] 
(4)   Prepare for beam angles 6.67 [4.25, 9.08] 
(5)   First beam angle 1.00 [1.00] 
(6)   Move gantry arm 1.00 [1.00] 
(7)   Second beam angle 1.00 [1.00] 
(8)   Move gantry arm 1.00 [1.00] 
(9)   Third beam angle 1.00 [1.00] 
(10) Discharge patient and reset gantry room 4.83 [2.83, 6.83] 
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hospital staff. An outpatient is assumed to have a 5% chance of absenteeism. The arrival 
time of an outpatient is distributed within 18 minutes on either side of the patient’s 
scheduled arrival time (Alexopoulos et al. 2008). Each patient is assigned a treatment 
plan that requires protons to be delivered from one, two, or three beam angles. Each 
treatment plan occurs with the same frequency. Finally, each patient has a scheduled arri-
val time, which may be based on the patient’s inpatient status or treatment plan. 
Upon arriving, a patient enters any available imaging room. If an imaging room is not 
available, the patient stays in the waiting room and waits for an imaging room to become 
available (Step 1 from Table 4-3). The priority of waiting-room patients to enter an imag-
ing room varies between experiments. The default is first come, first served (FCFS). The 
center contains five imaging rooms which are attached to exactly one of the five gantry 
rooms. In the imaging room, the patient is loaded onto a patient transporter, immobilized, 
and receives a CT scan. Upon completion of the tasks in the imaging room (Step 2), if the 
gantry room associated with the imaging room is available, the patient is transported to 
the gantry room (Step 3). Otherwise the patient waits in the imaging room for the gantry 
room to become available. 
 When arriving in the gantry room, the patient transporter docks with the gantry 
arm in preparation for delivery of the proton beams (Step 4). After finishing the delivery 
of protons, there is a 60-second delay before the cyclotron is able to deliver protons to a 
new room. If no rooms require the cyclotron, the beam can be switched to a room in an-
ticipation of the next patient to receive protons. If the cyclotron is busy or the beam needs 
to be switched to deliver the protons, a wait time is incurred in the gantry room. Between 
the delivery of protons from each prescribed angle (Steps 5, 7, 9), the gantry arm must 
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rotate (Steps 6, 8). One-beam plans omit Steps 6 through 9 and two-beam plans omit 
Steps 8 and 9. After receiving the protons, the patient dismounts the transporter and 
leaves the gantry room (Step 10). The room is prepared for the next patient. For each 
scheduling procedure, patient mix, and traffic mix, 100 days of arrivals were simulated. 
  Some experiments used a different distribution of late arrivals to simulate high 
congestion due to the urban location of the center. In 2012, Baltimore had the 17
th
 worst 
congestion in the nation according to INRIX, a traffic data service (Thomson 2013). The 
average commuter spent 25.7 hours in traffic over the course of the year. The Maryland 
Proton Treatment Center is located near downtown and would be exposed to some of the 
worst traffic conditions in the city. During peak rush hour commutes (8am to 9am and 
5pm to 6pm) the median commute time for highly traveled sections is between 2.4 and 
2.7 times that of off-peak hours according to the 2012 Maryland State Highway Mobility 
Report (2012). Between 18% and 29% of highway miles traveled during peak hours are 
done in moderate congestion (taking greater than 30% more time than under normal con-
ditions). During the worst 5% of days the commute can be between 5.6 and 6.8 times as 
long for some sections. The increased congestion and variability of traffic time leads to 
greater uncertainty in the arrival of outpatients scheduled during these hours. The patient 
arrival distribution is likely to be skewed late in addition to the greater variability of arri-
val time. Patients will be traveling from different locations and adjust for traffic different-
ly in making their own decisions for commuting. 
To model the effects of periods of high congestion, outpatients scheduled during peak 
traffic hours (8am to 9am and 5pm to 6pm) have a uniformly distributed variable between 
0 and 10 minutes added to their arrival time to represent the effect of traffic under normal 
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weekday conditions. This uniform variable is in addition to the triangular late and early 
arrival distribution which allowed for patients to arrive during an eighteen minute win-
dow to either side of their scheduled time. Every twentieth day had an additional 10 mi-
nute delay added to all outpatients scheduled during peak traffic hours, these ten minutes 
represent an abnormally high traffic day (usually caused by an accident or construction 
which would affect all drivers on a stretch of road). The hours immediately preceding and 
following peak traffic hours had a uniformly distributed variable between 0 and 5 
minutes added to their arrival time to better represent the traffic that leads up to and fol-
lows peak traffic. 
4.5 Extended Simulation Results 
4.5.1 Mixtures of in-patients and out-patients 
In previous work (Price et al. 2013), we produced a large decrease in patient wait time by 
ordering patients based on the number of beam angles used in their treatment plans. Our 
work showed that the near maximum throughput for a five imaging room and five gantry 
room facility was 13.33 patients per hour. The patients were sequentially ordered, begin-
ning with a one beam angle plan, followed by a two, then a three beam angle plan, repeat-
ing this ordering throughout the day. Since the cyclotron is the limiting resource of the 
facility, this schedule distributes patients who require more beam angles evenly. These 
patients arrived at the same uniform rate, but experienced only 70% the wait time of un-
ordered patients. Further analysis of patient wait times showed that not all patients had 
the same experience. In Table 4-4, we see that patients with one beam treatment plan 
(who follow three beam treatment plans in this scheduling scheme) have longer treatment 
75 
 
times than two and three beam treatment plans. The longer wait time is due to the amount 













1 Beam 0.04 0.52 3.25 3.81 
2 Beam 0.05 0.47 2.38 2.90 
3 Beam 0.04 0.41 1.72 2.17 
All Patients 0.04 0.46 2.45 2.96 
 
Table 4-4: Mean wait time of patients by number of beams used in treatment plan for se-
quential ordering schedule with evenly spaced arrivals at a rate of 13.33 patients per hour. 
All patients arrive at their scheduled time. 
 
The different wait times based on the treatment plan suggests that the time between 
arrivals should be adjusted based on the treatment plan of the preceding patient. An ad-
justed spacing was used to more evenly distribute the wait times among patients being 
treated with each of three types of treatment plans.  Adjusted spacing means a new pa-
tient will arrive more quickly after a patient who requires only a single beam angle and 
later after a patient requiring three beam angles. In Table 4-5, we show the results of 
schedules that use combinations of adjusting the arrival spacing and arrival ordering. 
While ordering patients by treatment plan and adjusting the spacing order have large ef-
fects on total wait times, taken together they show little improvement in waiting time 
over sequential ordering alone. Though using both adjusted spacing and sequential order-




Despite all patients arriving at their scheduled appointment time, the stochastic nature 
of the treatment time causes about 38% of patients to complete treatment in a different 
order than they arrived. When early and late arrivals are included in the model the differ-



















































Adjusted Spacing  
Sequential Order 
0.07 0.47 2.41 2.94 2.78 
 
Table 4-5: Mean waiting time of patients scheduled without regard to treatment plan 
(random order) and scheduled sequentially according to treatment plan (sequential order) 
using evenly spaced arrivals (even spacing) and adjusted arrival times based on treatment 
plan of preceding patient (adjusted spacing). All schedules have an average  arrival rate 
of 13.33 patients per hour. 
 
Figure 4-8 shows how waiting times for the four schedules increase as the proportion 
of outpatients increases. Outpatients increase wait times by not arriving at their scheduled 
time, but can reduce waiting time too, due to absenteeism. The uncertainty in patient arri-
val time of outpatients increases the wait times more for sequential schedules (adding 
more than 90 seconds of waiting time), than for non-sequential schedules (less than 50 
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seconds for evenly spaced patients). By evenly distributing outpatients throughout the 
day, one might expect to improve performance by having a more uniform experience. 
Scheduling with respect to outpatient status does not, in general, reduce patient wait time 
very much. As can be seen in Figures 4-9, there is little difference in total wait times 
when compared to Figure 4-8. Only the “adjusted and random” curve was slightly im-
proved by taking into account outpatient status.  
 
 
Figure 4-8:  Total patient wait time as a function of percentage of outpatients randomly 
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Figure 4-9: Total patient wait time as a function of percentage of outpatients evenly dis-
tributed through schedule. 
4.5.2 Block Scheduling 
We are now interested in determining the effects of block scheduling. By scheduling 
several patients to arrive simultaneously, the disruption to the system of any one of them 
arriving late is reduced. We schedule patients to arrive on the quarter hour in groups of 
three or four (maintaining an average hourly throughput of 13.33 patients). Figure 4-10 
shows that the ordering patients by treatment plan is still important for decreasing total 
patient waiting time. This leads to more patients in the waiting room at the same time, 
especially when there is a high percentage of inpatients. In Table 4-6, we see that perfor-
mance actually improves with the introduction of outpatients (and by extension early and 
late arrivals). Note that while exact scheduling  outperforms block scheduling for every 
combination of inpatients and outpatients tested, exact scheduling sees a 66% increase in 
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uling has only a 12% difference between its shortest wait time and its longest. When 














0 1.15 0.71 2.78 4.63 
25 0.83 0.75 2.89 4.48 
50 0.77 0.81 3.01 4.59 
75 0.79 0.86 3.07 4.71 
100 0.91 0.94 3.14 4.99 
 
Table 4-6: Average wait times for varying percentage of outpatients with 15 minute 
blocks, with an average arrival rate of 13.33 patients per hour. 
 
 
Figure 4-10: Ordering patients by treatment plan results in between 10% improvement 
(for 100% outpatients) and a 20% improvement (for 0% outpatients) in total wait time 
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We compared three decision algorithms to determine which patient is first to be ad-
mitted to an imaging room. First come, first served gives the baseline performance. In 
Table 4-7, we see that patients who arrive late have a shorter wait time than those who 
arrive on time. This is due to a shorter wait time in the waiting room, which occurs when 











Early 0.65 0.90 3.24 4.79 
On 
Time 0.88 0.82 2.91 4.61 
Late 0.68 0.78 3.06 4.52 
 
Table 4-7: Wait time for patients who arrive early, on time, and late when given first 
come, first served priority in 15 minute blocks with average arrival rate of 13.33 patients 
per hour. 
 
Taking into account that late arrivals should not be rewarded for their tardiness, we 
implement an ordering of admittances (Table 4-8) from the waiting room to an imaging 
room. In Table 4-9, we see that by applying the priority ordering the wait times are redis-
tributed, thereby reducing the wait times of early and on time patients. The priority order-
ing ensures that late arrivals have the longest wait time of any group. We next tried to 
determine if it is possible to reduce the wait time of block scheduling by admitting pa-
tients in a smarter order. By admitting patients to an imaging room based on their treat-
ment plan, a 4% improvement in wait times can be achieved over simple first come, first 
served. This is equivalent to the improvement for the early and on-time arrivals in the 





1. Early/On Time Ar-
rivals from Previous 
Block 
First priority is given to patients, who arrived early or on time, 
still waiting for treatment from previous blocks. 
2. Early/On Time Ar-
rivals from Current 
Block 
Following the completion of early and on time patients from 
the previous block, patients from the current block arriving 
early or on time are treated FCFS. 
3. Late Arrivals After all patients arriving early or on time from all previous 
blocks and the current block are treated, late arrivals are seen 
FCFS. 
4. Early Arrivals from 
Next Block 
Finally, after all patients in the waiting room from previous 
blocks and the current block have been assigned to an imaging 
room, early arrivals from the next block can be seen. 
 
Table 4-8: List of priority groups when admitting to an imaging room. Within each group, 












Early 0.59 0.83 3.18 4.60 
On-
Time 0.79 0.79 2.92 4.50 
Late 0.80 0.81 3.07 4.68 
 
Table 4-9: Wait time experienced by patients who arrive early, on-time, and late when 
served using priority listed in Table 4-6 with 15 minute blocks with average arrival rate 
of 13.33 patients per hour. 
 
 The major strength of block scheduling is its resilience to high uncertainty of arrival 
times. Due to the traffic conditions around the site of the treatment center we wished to 
test performance of block scheduling with greater variability of arrival time. Given the 
increased variability of outpatient arrival time during rush hour it is reasonable to want to 
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schedule inpatients during this time window to reduce the commute time of outpatients 
coming for treatment and to minimize any disruption caused by their potentially in-
creased tardiness. As seen in Table 4-10, however, block scheduling is robust, having less 
than 4% longer wait times over the course of the day. It should be noted that while 
scheduling inpatients for treatment during high traffic hours may be more convenient for 











Conditions 0.79 0.86 3.07 4.71 
High Traffic 
(even mix) 0.84 0.92 3.13 4.89 
High Traffic 
(inpatients) 0.93 0.88 3.10 4.90 
 
Table 4-10: Wait time experienced by patients with 15 minute blocks with average arrival 
rate of 13.33 patients per hour with a 75% outpatient mix. Simulated days include either a 
constant late arrival function (Normal Conditions) or include increased traffic for rush 
hour periods (High Traffic). Under high traffic conditions the patient mix either remained 
the same as the rest of the day (even mix) or switched to treating only inpatients (main-
taining a daily average of 75% outpatients). 
Thirty seven and one half percent of outpatients will be affected by the high traffic 
conditions when out patients remain uniformly mixed with inpatients throughout the day. 
These outpatients experience an increased probability of late arrival and a greater vari-
ance of arrival times. Despite these changes less than a 4% increase in average wait time 
is experienced. Similar to using block arrivals with only inpatients, we see an increase in 
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waiting room time when inpatients are scheduled to arrive during the hours of peak traf-
fic. 
4.5.3 Equipment Failures 
The facility layout uses remote positioning of patients to help transfer patients from 
the imaging room to the gantry room. Each imaging room is associated with a single gan-
try room and vice versa. When an imaging room or gantry room is out of operation, the 
facility changes from a five imaging and five gantry room facility to a four imaging and 
four gantry room facility. If there is an equipment failure, it is important that patients still 
receive their scheduled treatment.  Price et al. (2013) explored the differences in through-
put of multiple facility configurations. They found that there is a decreasing return in 
throughput for each additional gantry room. Thus, closing a gantry or imaging room will 
not reduce throughput by 20%. In fact, a fifth gantry room allows for only 5.7% greater 
throughput. The patients seen in 15 hours of operation of the five gantry room system, 
would take four gantry rooms an additional 50 minutes. If patients are not rescheduled, 
this translates to an extra four minutes in the waiting room for each hour a gantry room is 
closed. Taking into account patient absenteeism, about one patient per 90 minutes needs 
to be rescheduled in order to maintain short wait times. Thus, an inpatient can be selected 






Figure 4-11: Accumulation of wait time throughout day with one gantry room closed, 
75% outpatient, and rescheduling one patient every 90 minutes. 
 
commuting patients. Figure 4-11 shows the average wait time of 100 simulated days for a 
mixture of 75% outpatients. 
4.5.4 Special Needs 
Pediatric patients have been shown to receive some of the greatest marginal benefits 
of proton therapy when compared to traditional IMRT (Mirabell et al. 2002, St Clair et al. 
2004). The benefit of being able to deliver a radiation dose to a precise location with little 
incident radiation to surrounding tissue is contingent upon the radiation being delivered 
to the correct location. This is why an image is taken before treatment and why patients 
are immobilized. Pediatric patients require anesthesia in order to minimize movement 
during the imaging and treatment processes. The anesthesia is applied before patient im-




























the gantry room to enter a recovery room. The anesthesiology team follows the patient 
from the imaging room, to the gantry room, to recovery, where a nurse stays with the pa-
tient until fully recovered. The bulk of the team’s work is done in the imaging room, add-
ing an extra five minutes to the preparation time. There is an extra two minutes of time in 
the gantry room, though beam delivery and gantry arm rotation times remain unchanged. 
As noted previously, a five gantry room facility has extra capacity. Despite the extra time 
required in the imaging room and the gantry room a single anesthesiology team does not 
affect throughput, while two teams will have a slowing effect of less than 2%. A single 
anesthesiology team with equipment in a single imaging room and gantry room is able to 
treat 8.5% of patients (or about 1.13 patients per hour). In order to minimize the amount 
of time a gantry room is unoccupied, the patient preceding pediatric patients should have 
long (three beam) treatment plans. 
4.6 Conclusions 
Due to the excess capacity of a five gantry room facility, adjusting for equipment failures 
requires the rescheduling of one out of 20 patients. This excess capacity, allows for pa-
tients with special needs to be treated without affecting throughput. We show that, while 
it is important to take into account all prior knowledge when scheduling a patient, waiting 
time improvements from doing so are reduced somewhat by the reality of patient tardi-
ness and absenteeism. There is little extra wait time added (about 6%), in switching from 
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 Each year over 900,000 men worldwide are diagnosed with prostate cancer. In the 
United States alone, we spend almost $12 billion in treatment. With so many men im-
pacted by the disease and so many resources being spent on treatment operations research 
has an opportunity to make a big impact in many ways. Operations research techniques 
have been applied to screening with prostate specific antigen, detection of the disease 
through MRI, and treatment of the disease. We analyze the research done using opera-
tions research techniques and seek to quantify the impact it has had on the treatment of 





 Based on 2008-2010 data, approximately 15.3% of men will be diagnosed with pros-
tate cancer during their lifetime. In 2014, about 233,000 men in the United States will be 
diagnosed with prostate cancer making it the most common form of cancer among men. 
In 2011, more than 2.7 million men in the United States were estimated to be living with 
prostate cancer. Prostate cancer is the second leading cause of cancer deaths among men 
with more than 29,000 deaths projected in the United States for 2014. All of the preced-
ing numbers are taken from the Surveillance, Epidemiology, and End Results (SEER) 
program in the United States [17]. 
 About $11.85 billion is spent annually in the United States on the screening, detec-
tion, and treatment of prostate cancer (Mariotto et al. [13]). Clearly, improving the 
screening, detection, and treatment of prostate cancer has the potential to increase the 
lifespan and improve the quality of life for thousands of men.  
 Over the years, the battle against prostate cancer has been joined by researchers and 
practitioners who have used a wide variety of operations research (OR) models and 
methods to help screen, detect, and treat the disease. Specifically, a search on the Web of 
Knowledge using “prostate/prostatic and operations research method” revealed 402 pub-
lished papers in 13 categories over the past 15 years or so (see Table 5-1). The citation 
count by year for these 402 papers is given in Figure 5-1. Clearly, this group of papers 
has been cited thousands of times since 2000. 
In order to convey the importance and impact of OR methods and models in prostate 
cancer research, we annotate a representative set of 49 papers (selected from the 402 pub-




 OR Model/Method            Number of Papers 
 Machine learning           125 
 Markov model                             102 
 Markov chain    58 
 Integer programming   25 
 Linear programming   22 
 Optimal control   17 
 Microsimulation   17 
 Markov decision   16 
 Discrete event simulation    7 
 Dynamic programming    5 
 Analytic hierarchy process    5 
 Agent-based model     2    
 Multi-attribute utility model    1   
 _______________________________________ 
 Total              402 
 
Table 5-1:Count of OR papers in prostate cancer research on the Web of Knowledge 
(2000-2014). 
 
antigen screening (quantifying the effects of screening, predicting prostate cancer, screen-
ing policy), detecting tumors (improving biopsies, using magnetic resonance imaging to 
detect prostate cancer), and treatment (staging, active surveillance, hormone therapy and 
tumor size, brachytherapy, patient choice, recurrence, costs). They use almost all of the 
models and methods listed in Table 5-1 and some techniques that are not (e.g., nomo-
grams). A categorization along these lines is given in Table 5-2. These papers are well 
cited (more than 1,900 citations in the Web of Knowledge as of April 24, 2014), interest-
ing, and diverse in their applications. 
In Sections 2, 3, and 4, we discuss OR models and methods for screening, detection, 
and treatment, respectively. Annotated papers listed in the bibliography are cited with ( ), 
while papers not appropriate for the bibliography are cited with [ ] and listed in the refer-
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ences. In each section the annotations are given in reverse chronological order, starting 
with the most recent paper. We provide conclusions in Section 5. 
 
 
          
Figure 5-1: Number of citations by year for 402 papers using OR methods and models on 
prostate cancer research from the Web of Knowledge  search (April 24, 2014). 
 
Table 5-2: OR models and methods used in prostate cancer research. 
 
   Paper Number   
Area   in Bibliography               Model/Method 
Data Mining  1    KNN  
   4    GA, KNN, PCA, SVM 
   6    CL 
   7    SVM 
   8    RPART, RT 
   17    CART, RT 
   20    QUEST, RT 
   24    ICA, NMF, PCA, PLS, SVM 
   26    ANN 
   30    ANN 
   33    ANN, SVM 
   37    ANN, NOM 
   38    ANN, FKNN 
   39    ANN, FKNN 
   40    ANN, NOM, CART, RT 













2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014
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Table 5-2. (continued) 
 
Decision Aiding/  3    DT 
Analysis   5    MAU 
   11    MM 
   29    AHP 
   41    MAU 
    
Mathematical  15    GA 
Programming  16    GA 
   27    MIP 
   28    MIP 
 
Simulation  9    MIC, MM 
   10    MC 
   12    MIC, MM 
   13    MIC, MM 
   14    MIC, MM 
   18    MIC, MM 
   19    MIC 
   21    MC 
   36    MC, MM 
   42    TDS 
   46    MX 
   47    MIC, MM 
   48    MDP 
   49    MDP 
 
Statistics  2    LR 
   22    NOM 
   23    NOM 
   25    KF 
   31    LR    
   32    NOM 
   34    TSLS 
    35    LR 
   43    NOM 
    45    LR 
_____________________________________________________________________ 
AHP Analytic Hierarchy Process  MIP Mixed Integer Program 
ANN Artificial Neural Network   MM Markov Model 
CART Classification and Regression Tree  MX Mixture Model 
CL Clustering    NMF Nonnegative Matrix Factorization   
DT  Decision Tree    NOM Nomogram 
FKNN Fuzzy K-Nearest Neighbor  PCA Principal Components Analysis 
GA Genetic Algorithm   PLS Partial Least Squares 
ICA Independent Component Analysis  QUEST Quick, Unbiased, and Efficient Statistical Tree 
KF Kalman Filter    RPART Recursive Partitioning and Regression Tree 
KNN K-Nearest Neighbor   RT Regression Tree 
LR Logistic Regression   SVM Support Vector Machine 
MAU Multi-Attribute Utility   TDS Three Dimensional Simulation 
MC Monte Carlo Simulation   TSLS  Two Stage Least Squares 





5.2 Prostate Specific Antigen Screening 
 Since the FDA approved the PSA test for prostate cancer in 1994, millions of men 
have been tested. In the 2010 census, there were over 67 million American men over the 
age of 40 (Howden and Meyer [10]) whose screening decisions might be affected by 
screening recommendations. In 1980, prior to PSA screening, there were 106.0 new cases 
of prostate cancer per 100,000 men (SEER [17]). By 2000, after PSA screening was in-
troduced, the rate jumped to 183.1, an increase of 72% [17]. Screening accounts for 89% 
of new prostate cancer diagnoses, with screen detected tumors being more clinically lo-
calized than clinically detected tumors (tumors detected due to the onset of other symp-
toms) (Hoffman et al. [9]). In 2009, Medicare spent an estimated $447 million on PSA 
screening (Ma et al. [12]). However, the benefits of screening are unclear. In 2012, the 
U.S. Preventive Service Task Force (Moyer [14]) recommended against PSA screening in 
men of average risk due to its limited benefit and potential harm from unnecessary treat-
ment. There are three important questions that the field of operations research has helped 
address with respect to prostate cancer screening. What are the effects of prostate cancer 
screening? How can the use of the PSA test in detecting prostate cancer be improved? 
What should be the policy for PSA screening? 
5.2.1 Quantifying the Effects of PSA Screening 
The benefit of PSA screening is the early diagnosis of prostate cancer. The time 
between when the cancer is diagnosed by screening and when it would have presented 
clinically in the absence of screening is the lead time. The lead time is important because 
early treatment of the cancer can help improve outcomes.  
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Typically, prostate cancer is slow growing with a low mortality rate. Many men 
diagnosed with prostate cancer due to screening may never have been affected by pros-
tate cancer within their lifetimes if the cancer had gone undetected. Men who are diag-
nosed due to screening and would not have presented the clinical symptoms within their 
lifetimes are referred to as having been overdiagnosed. Overdiagnosis can lead to over-
treatment, i.e., treatment of a likely indolent cancer, resulting in some men unnecessarily 
living with the side effects of surgery or radiation therapy, with potential negative effects 
such as urinary and bowel dysfunction, erectile dysfunction, and loss of fertility. An im-
portant question is: Do the benefits from early diagnosis outweigh the risks of overdiag-
nosis? 
There have been two major clinical trials focused on the effect of PSA screening 
on mortality rates from prostate cancer. The European Randomized Study of Screening 
for Prostate Cancer (Schröder et al. [16]) found a 20% decline in mortality due to prostate 
cancer as a result of screening. The U.S. Prostate, Lung, Colorectal, and Ovarian Cancer 
Screening Trial (Andriole et al. [2]) found that screening had no statistically significant 
effect on reducing mortality. These conflicting results have contributed to the controversy 
over the benefits and harms of prostate cancer screening. These contradictory results have 
been attributed to a number of causes of bias, such as contamination of the control arms 
by men who received screening.    
 The failure of clinical trials to provide definitive answers about the merit of PSA 
screening provides motivation for the use of OR models to answer these questions. We 
summarize six papers that used statistics, Markov modeling, and simulation to estimate 






Gulati et al. (19) used a simulated population to build a nomogram for estimating the 
probability that a screen-detected prostate cancer would not have been diagnosed within 
the patient’s lifetime. Overdiagnosis rates in the United States are estimated to be be-
tween 23% and 42% for screen-detected prostate cancer. This high rate of overdiagnosis 
leads to overtreatment which can be detrimental to a patient’s health and happiness. 
Overdiagnosis is not directly observable. After an individual has screen-detected prostate 
cancer and has been treated, we do not know if the cancer would have been diagnosed 
within the individual’s lifetime without screening.  Using a microsimulation model of the 
progression of the disease, a population of 10,000 simulated prostate cancers was devel-
oped to train a logistic regression model indicating if a patient was overdiagnosed. Patient 
age, cancer Gleason score, and PSA level were used to predict if the patient had been 
overdiagnosed. The probability of overdiagnosis increased with age, decreased with PSA 
level, and decreased if the Gleason score was greater than or equal to seven. The nomo-
gram had an area under the ROC curve (AUC) of 0.75. 
 
Estimates of lead time and overdiagnosis due to PSA screening varies widely in the lit-
erature. Draisma et al. (9) used three independently developed models to compare pre-
dicted results for lead time and overdiagnosis of prostate cancer. The lead time can be 
interpreted three ways: lead time for non-overdiagnosed cancers only, censored lead 
times for both non-overdiagnosed and overdiagnosed cancers with lead time for overdi-
agnosed patients stopping at death, and uncensored lead times (for overdiagnosed pa-
tients, these continue until the patients would have been clinically diagnosed). The au-
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thors used two microsimulation models from the literature and a statistical mixed model 
(Tsodikov, Szabo, and Wegelin (46)) to compare the estimates of lead times and overdi-
agnosis. A microsimulation model simulates the health outcomes for each patient of the 
population. The overdiagnosis estimates varied from 23% to 42% of all screen-detected 
cancers, which is consistent with population-based trial estimates. The non-
overdiagnosed lead times ranged from 5.4 to 6.9 years, which allows for treatment to 
begin at an earlier stage, thereby improving outcomes. The censored lead time ranged 
from 5.7 to 7.8 years (this includes the time that patients who would die from other caus-
es are diagnosed with prostate cancer). The uncensored lead time ranged from 7.2 to 10 
years (this includes the time that patients who die from other causes would gain before 
diagnosis without PSA levels). 
 
Etzioni et al. (13) used the microsimulation model to measure the effect of PSA screening 
on advanced stage prostate cancer and prostate cancer mortality. In 1986, PSA screening 
started in the United States. From 1990 to 1999, there was a 21% decline in observed 
mortality from prostate cancer. The model compared outcomes with and without PSA 
screening (with some percentage of men receiving biopsies based on PSA level). PSA 
screening accounted for 80% of the observed drop in the incidence of advanced prostate 







Schröder and Kattan (37) analyzed the results of 36 nomograms and ANNs from the lit-
erature to compare their efficacy against using PSA level alone. The authors reviewed 23 
papers that used three or more variables for risk assessment in the form of a nomogram or 
ANN. Model accuracy was compared using the AUC when available; otherwise sensitivi-
ty and specificity were used. The studies drew from different populations, with some in-
cluding referred patients and those participating in screening studies. The populations 
ranged in size from 151 to 8,851 patients. The models considered a variety of input vari-
ables, depending on available information. Age, family history, and PSA velocity often 
lacked significance and were not included in the final models. Model validation on exter-
nal populations is an important step in arguing generalizability. Ten of the 36 models 
were externally validated on a total of 16 external populations. In 13 external validations, 
the AUC decreased, in two it increased, and in one it stayed the same. In general, the 
models improved the AUC over PSA alone by approximately 0.10. The authors raised 
important questions about the independence of the input variables, some of which, like 
age, prostate volume, and PSA level, have relationships that are well understood. 
 
Tsodikov, Szabo, and Wegelin (46) constructed a statistical model to estimate lead time, 
overdiagnosis, and other relevant characteristics of prostate cancer screening. The authors 
used a three-stage model of the natural history of the disease (disease-free stage, pre-
clinical stage, clinical stage). Overdiagnosis was defined as the fraction of screening de-
tected cancers that would not be detected in the absence of screening. Lead time was de-
fined only for non-overdiagnosed patients. The study was limited to men over 50, since 
the probability of prostate cancer is small for men under 50. Data on 350,000 cases of 
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prostate cancer were taken from the Survey and Surveillance, Epidemiology and End Re-
sults (SEER) database and population counts for the relevant areas of diagnosis. To simu-
late PSA testing schedules to be used by the statistical model, a simulator for PSA sched-
ules from the National Cancer Institute’s Statistical Research and Applications Branch 
based on data from the National Health Interview Survey and SEER was used. The statis-
tical model estimated a 6-year mean lead time and 25% overdiagnosis among detected 
patients. 
 
Etzioni et al. (14) applied a microsimulation of PSA screening and prostate cancer devel-
opment to estimate the rate of overdiagnosis in a hypothetical cohort of men.  A hypo-
thetical cohort based on census data of two million men between 60 and 84 years old in 
1988 was used. The simulation was run on the group with and without screening. Testing 
and detection rates for the model varied by year, age, and race. The model used three, 
five, or seven years mean lead time to estimate how long before the cancer would have 
been clinically detected without screening. Overdiagnosis was estimated at 28.8% for 
white men and 43.8% for black men using five-year and seven-year lead time estimates, 
respectively. The overdiagnosis rate was sensitive to the mean lead time provided by 
screening, but not to the relative frequency of screen-detection. When the lead time was 
reduced to three years, the overdiagnosis rate dropped to 17.7% for white men and 20.3% 




5.2.2 Predicting Prostate Cancer from the PSA Level 
When the FDA approved the use of PSA level to test for prostate cancer in 1994, 
a threshold of 4 ng/mL was used as the upper limit for a normal PSA level (FDA [7]). 
Using a PSA threshold of >4ng/mL to indicate a need for a biopsy, about 20% of prostate 
cancers would be detected and 30-40% of patients without prostate cancer would be 
above this threshold (Greene et al. [8]). In 2009, the American Urological Association 
(AUA) recommended against using a single threshold level, and advocated the use of 
additional information to improve detection (Greene et al. [8]). For example, PSA level 
changes with age. 
Improving the predictive value of PSA screening means fewer unnecessary biop-
sies which carry the potential for infection, temporary erectile dysfunction, and lingering 
urinary problems. In the eight papers summarized, researchers applied machine learning 
and statistical methods to improve the prediction of prostate cancer by increasing sensi-
tivity (probability of correctly identifying prostate cancer) and, in some cases, identifying 





Prostate biopsies can have one of five outcomes: benign, atypical small acinar prolifera-
tion (ASAP), high-grade prostatic intraepithelial neoplasia (PIN), non-significant prostate 
cancer, or clinically significant prostate cancer. Benign means that the biopsy was non-
cancerous. ASAP means the biopsy result was indeterminate and could not be classified 
as benign or malignant. PIN is thought to be a precursor of a malignant tumor.  Non-
significant prostate cancer is considered not life threatening, while clinically significant 
prostate cancer typically requires treatment. Lawrentschuk et al. (26) constructed a poly-
chotomous logistic regression model and an artificial neural network model to predict 
biopsy results. Age, PSA level, DRE, presence of hypoechoic lesion (a visible abnormali-
ty) during transrectal ultrasound (TRUS), and TRUS prostate volume for 3,025 men with 
PSA level less than 10 ng/mL who underwent a TRUS-guided biopsy were used to con-
struct the models. The models were trained on two-thirds of the data and tested on the 
remaining one-third. The regression and neural network models correctly identified be-
nign tumors 86% and 88% of the time, respectively and clinically significant prostate 
cancer 65% and 66% of the time, respectively. Neither model correctly identified any 
ASAP/PIN outcome. Both models predicted only 2% of non-significant prostate cancer 
correctly. Prostate volume and a positive TRUS lesion were the most significant in cor-
rectly identifying patients with clinically significant prostate cancer from benign biopsy 
results with odds ratios of .19 and 5.2, respectively. The authors concluded that additional 
predictors would be necessary to correctly distinguish among the five outcomes. 
 
Many predictive models for prostate cancer biopsy results are developed using a popula-
tion of patients referred for early cancer detection or urinary tract symptoms. Therefore, 
99 
 
these models may not generalize to all men being screened for prostate cancer. Sooria-
kumaran et al. (43) used a population of screened patients to construct two predictive 
models in order to reduce unnecessary biopsies. The authors began with 3,838 men from 
the Tyrol Prostate Cancer Screening Study. They removed patients missing total PSA 
(tPSA) level, DRE, prostate volume, or percent free PSA (fPSA), leaving 2,271 patients. 
The authors used a urologically referred population of 599 patients, from the Weill Cor-
nell Medical College, for external validation. Multivariate logistic regression models 
were constructed where Model 1 used age, DRE, and tPSA, and Model 2 added percent 
fPSA. Nonlinear relationships between the features and the outcome were evaluated us-
ing a multiple fractional polynomial method. A bootstrap method with 200 bootstrap 
samples was used during internal validation. The AUC for the two models were .691 and 
.710, respectively.  The authors then constructed nomograms based on the two models. If 
patients with a 10%  or greater risk of cancer were biopsied, then 30 biopsies (1.3%) 
would be avoided and two cancers (.3%) would be missed by Model 1 applied to the Ty-
rol sample. Model 2 avoided 95 biopsies (4.2%) and missed six cancers (.9%). When ap-
plied to the urologically referred population for patients with 20% or greater risk of can-
cer, Model 1 avoided 126 biopsies (21.0%) and missed 18 cancers (9.8%). Model 2 
avoided 169 biopsies (28.2%) and missed 19 cancers (10.3%). The authors concluded 
that their models had sufficient predictive power to aid in clinical decision making re-





Gülkesen et al. (20) developed a decision tree to classify the risk level of prostate cancer 
for 750 patients with serum fPSA and PSA levels less than or equal to 10 ng/mL who 
underwent prostate biopsy at the Urology Department of Akdeniz University Hospital. 
Age, PSA level, free PSA level, percent-free PSA, DRE 1 (with three possible outcomes 
for prostate cancer: negative, suspicious, or positive), and DRE 2 (with two possible out-
comes for prostate cancer: negative or not negative) were used to construct the model. 
The QUEST algorithm (quick, unbiased, and efficient statistical tree) produced a model 
using a training set of 562 patients. The algorithm classified the patients into five groups 
with the risk of cancer ranging from 0% to 25%. The AUC was .62 compared to .68 for 
logistic regression using the same features. The lowest risk group, with no prostate cancer 
in either the training or testing sets, identified by the decision tree had patients with a 
PSA level less than or equal to 5.98, a negative DRE, and an fPSA level greater than .81.  
 
Nam et al. (32) constructed a nomogram to assess the risk of a patient having prostate 
cancer with a Gleason score greater than or equal to seven. In a data set of 3,010 men 
with PSA levels greater than 4.0 ng/mL or abnormal DREs referred to the Prostate Cen-
ters of the University of Toronto, 2,700 had PSA levels less than 50 ng/mL, were able to 
provide complete information including family history of prostate cancer, and consented 
to participate in the study. An additional 408 men with a PSA level less than or equal to 
4.0 ng/mL agreed to undergo a biopsy and were added to the study. Age, ethnicity, family 
history, symptom score, PSA level, ratio of free PSA to total PSA, and DRE were used as 
predictor variables. A model to predict the probability of no cancer, low-grade cancer 
(Gleason score less than or equal to six), and high-grade cancer (Gleason score greater 
than or equal to seven) was constructed using ordinal logistic regression. The logistic re-
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gression model used data from 2,108 patients and was tested on 1,000 patients. A nomo-
gram was designed using the results of the logistic regression model.  The AUC for pre-
dicting any prostate cancer was .74 based on the nomogram. The total AUC for predict-
ing high-grade cancer was .77 based on the nomogram. The logistic regression model 
with the full set of predictor variables performed much better than the model based only 
on PSA levels and DRE results, which had an AUC of .59. 
 
Aggressive prostate cancer, defined as having a Gleason score greater than or equal to 
seven, benefits from early detection and treatment. Spurgeon et al. (44) developed a clas-
sification and regression tree (CART) model to predict the presence of aggressive pros-
tate cancer in patients. Age, PSA level, PSAD, DRE, race, family history, vasectomy, 
transrectal ultrasound (TRUS) findings, and prostate volume for 1,563 consecutively re-
ferred men from the Portland Veterans Administration Hospital were used in the training 
and testing of the CART model.  The authors used 1,067 patients for training and 492 
patients for testing. Their model identified 43 of the 47 cancer patients with aggressive 
prostate cancer (91.5% sensitivity) and 149 of the 445 patients with Gleason score less 
than seven (31.9% specificity). When their model predicted a Gleason score greater than 
or equal to seven (i.e., aggressive prostate cancer), it was correct only 12.7% of the time. 






Thompson et al. (45) used a logistic regression model based on data from the Prostate 
Cancer Prevention Trial to create an online risk calculator based on data for 5,519 men in 
the control arm of the trial. The statistically significant model risk factors were race, age, 
family history, PSA level, digital rectal exam result, and whether the patient had a prior 
biopsy or not. The AUC for out of sample data, based on 4-fold cross validation, was ap-
proximately 70%, indicating satisfactory discrimination. A more recent revision of the 
model in 2012, referred to as PCPTRC 2.0, adds the ability to estimate the likelihood of 
low- and high-grade cancers (Ankerst et al. (2)). Statistics about the risk calculator web-
site indicate hundreds of thousands of visits in the last 48 months, suggesting the calcula-
tor is commonly used by physicians and/or patients.  
 
Garzotto et al. (17) developed a decision tree using classification and regression tree 
analysis (CART) to improve the accuracy of PSA tests. The authors trained their model 
using 1,433 consecutive referred patients who underwent an initial prostate biopsy proce-
dure. They used 5-fold cross validation with the cost of misclassifying cancer as normal 
three times more than the cost of classifying a normal prostate as potentially cancerous. 
They mirrored the medical decision process used by physicians by first creating a deci-
sion tree using only PSA and DRE data. Then they added demographic data and family 
history to identify patients at high risk of prostate cancer. Their model identified 278 of 
the 291 cancer patients (95.5% sensitivity) and 334 of the 882 noncancerous patients 
(37.9% specificity). If their model predicted a cancerous biopsy, it was correct 33.7% of 
the time. If their model predicted a negative biopsy, it was correct 96.3% of the time. Fur-
thermore, of the 15 cancer patients missed by the CART model, 14 had Gleason scores 





5.2.3 PSA Screening Policy 
 Researchers have tried to improve screening policies for men in the United States by 
analyzing when to start screening, how often to screen, and at what PSA level to receive a 
biopsy. In 2009, the AUA recommended that screening start as early as age 40 (Greene et 
al. [8]). In 2013, the AUA updated their guidelines and recommended against screening 
men at average risk of prostate cancer between the ages of 40 and 54 (Carter et al. [4]). In 
the six papers summarized, researchers used optimization and simulation to compare the 
effects of different screening policies on mortality, quality-adjusted life years (QALYs), 
overtreatment, and lead time. 
5.3 Detecting Tumors 
PSA screening is relatively inexpensive, costing between $17 and $62 (Ma et al. 
[12]). However, it is not a definitive test, because its sensitivity is too low to justify 
treatment for a patient. A biopsy is necessary for definitive diagnosis of prostate cancer. 
Typically, a biopsy involves taking 12 samples of the prostate using hollow core needles. 
The results are reviewed by a pathologist to provide an assessment which includes the 
Gleason grade of the cancer and other clinical factors associated with patient health out-
comes.  
In some cases, additional diagnostic tests may be used to provide information 
about the size, grade, and/or location of a tumor. These may include magnetic resonance 
imaging (MRI), or the use of additional biomarkers. There are a number of new bi-
omarkers that have been discovered, and some have recently received FDA approval, 
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such as the urine based PROGENSA prostate cancer antigen 3 (PCA3) test. Similar to 
PSA, the PCA3 test provides a score that can be used to predict the presence and grade of 
cancer (Filella et al. [6]).  
________________________________________________________________________ 
Gulati, Gore, and Etzioni (18) used a microsimulation model of prostate cancer to com-
pare 35 screening policies based on lives saved, overdiagnoses, and mean time of life 
saved. A microsimulation model simulates at the unit of individual patients. This model 
simulated the PSA growth and disease progression of 100 million men. Thirty-two 
screening strategies that used starting age (40 or 50 years), stop age (69 or 74 years), 
screening intervals (annual or biennial), and biopsy referral conditions (PSA level of 4 
ng/mL, PSA level of 2.4 ng/mL, PSA level of 4 ng/mL or PSA velocity of 0.35 ng/mL 
per year, or PSA level greater than 95
th
 percentile for age) were compared. The authors 
evaluated screening policies recommended by the American Cancer Society (ACS), the 
National Comprehensive Cancer Network (NCCN), and the medical literature. They 
compared results to a base plan of annual screening from age 50 to 74 with biopsy 
threshold set at 4.0 ng/mL. The NCCN plan had the greatest improvement on reducing 
cancer deaths and increased the mean time of life saved from 0.86 month to 1 month. 
However, the NCCN plan doubled the number of false negatives and increased the prob-
ability of over diagnosis from 3.3% to 6%. The ACS plan performed the same as the base 
strategy for lives saved and overdiagnoses, but reduced the number of tests conducted by 
nearly a quarter. Using age-specific PSA thresholds for biopsy referral reduced false 




Underwood et al. (47) constructed a simulation, based on a non-stationary, finite horizon 
Markov process, to model various PSA-based screening policies. Each screening policy 
was represented as a set of PSA thresholds for biopsy referral by age. They optimized 
these policies using a genetic algorithm and compared their results to policies presented 
in the literature. The simulation used 51,294 PSA levels from 11,872 men from Olmsted 
County, MN and age-specific death and incidence data from a variety of other sources. 
The authors judged the policies in terms of quality-adjusted life years (QALYs), giving a 
one-time penalty for unnecessary biopsies. The genetic algorithm converged on a plan 
that had less than annual screening between the ages of 54 and 76, with the threshold for 
a biopsy based on a PSA level set lower than the current standard. The optimized policy 
slightly improved the results of the best policy given in the literature, and indicated the 
maximum number of QALYs that screening policies could provide. Underwood et al. 
suggested that screening over a shorter time period, with lower PSA thresholds, might do 
the most to improve QALYs. 
 
Zhang et al. (48) constructed a partially observable Markov decision process to examine 
the benefits PSA screening to patients and society. Patients progress through health states 
(no cancer and cancer are not directly observable; treated, metastasis, and death are con-
sidered known) and observable PSA intervals. Each year a decision is made to perform a 
biopsy or defer the decision until the next time period. The objective was to maximize 
QALYs for a patient. Detriments to the quality of life were occurrence of biopsy, treat-
ment upon detection of cancer, long-term complications resulting from treatment, and 
symptoms from metastasis and its treatment. A secondary objective, from the societal 
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perspective, is to maximize the expected monetary value of the QALYs minus the costs 
of screening, biopsies, and treatments. Prostate cancer probabilities   conditional on PSA 
level were estimated using 11,872 patients from Olmsted County, Minnesota. A finite 
fixed-grid method was used to obtain the optimal policies for patients and society. The 
optimal policy from a patients perspective (maximizes QALYs) had screening stop at 76 
and improved QALYs by 0.131 over no screening and 0.165 over current policy (note 
that current policy underperforms no screening. The optimal policy from a societal view-
point stops screening at age 71 and improved QALYs by 0.110 over no screening and 
0.161 over traditional guidelines. 
 
Zhang et al. (49) used the partially observable Markov decision process model to exam-
ine prostate biopsy referral decisions. The optimal policy often took the form of a con-
trol-limit type policy, that is, a biopsy is performed only when the belief state for cancer 
exceeds a threshold value. There were three conditions for a control-limit type policy: 
annual probability of prostate cancer incidence is less than or equal to a multiple of the 
probability of treated patients developing metastasis, the annual probability of death from 
other causes is non-decreasing, and the annual probability of death from metastatic pros-
tate cancer is non-increasing. There exist conditions when it is optimal to discontinue 
biopsy referral at a specific age. The optimal policy was estimated to improve the Ameri-
can Urological Association’s age-adjusted guidelines by .115 QALYs (.306%). The au-
thors noted that personalized utility assessment, consideration of comorbidity, and family 




Prostate cancer screening strategies that use a PSA score vary in the age a patient begins 
screening, the threshold result from a PSA test to recommend a biopsy, and the time in-
tervals to receive screening. It is impractical to run randomized screening trials for all 
possible screening strategies. Ross et al. (36) constructed a Monte-Carlo simulation that 
tested a range of screening policies based on the number of prostate cancer deaths pre-
vented. They tracked the number of PSA tests and biopsies per 1,000 men taken over the 
entire run of the simulation. The simulation was based on a Markov model that transi-
tioned between no prostate cancer, three levels of cancer, and mortality due to prostate 
cancer and other causes. They simulated populations of one million men starting at 40 
years of age for 40 years. Eight policies (including a baseline of no screening) with dif-
ferent PSA thresholds, screening frequency, and age recommendations were tested. The 
medical standard at the time called for annual PSA testing from age 50 to 75 with a PSA 
score above 4 ng/mL requiring a biopsy. The authors constructed a policy of screening at 
ages 40, 45, and 50, and then every two years until 75 with the PSA level at  4 ng/mL. 
Their new plan reduced the lifetime biopsies per 1,000 men from 600 to 450 and the av-
erage number of PSA tests in a lifetime from 10.5 to 7.5. Prevented deaths increased to 
3.3 per 1,000 men from 3.2. 
 
Etzioni et al. (12) constructed a computer model to measure the effect of PSA screening 
strategies on years of life saved, PSA tests performed, false-positive PSA tests, and rate 
of over diagnosis. The authors constructed a simulation model of prostate cancer and its 
progression in the population using real-world data from the surveillance epidemiology 
and end result (SEER) registry. A Markov model simulated the disease progression of 
five-year birth cohorts. The mortality rates for all causes of death other than prostate can-
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cer and deaths due to prostate cancer were computed for each cohort. Clinical histories 
were developed for the patients that included date of clinical diagnosis of prostate cancer 
(in the absence of screening) and date of death not due to prostate cancer. Not all men 
develop prostate cancer. If the clinical diagnosis of prostate cancer was made before 
death from other causes, a history of disease progression was needed. Using the simulat-
ed progression of prostate cancer, natural histories were constructed for patients that in-
cluded dates for disease onset and progression of the cancer. PSA levels that resulted 
from screening were simulated and grew at different rates based on the health state of the 
prostate. Five screening strategies were tested: annual PSA screening with age-specific 
biopsy thresholds, biannual PSA screening with age-specific biopsy thresholds, annual 
PSA screening with >4ng/mL threshold, biannual screening with >4ng/mL threshold, and 
screening every five years with threshold of >4ng/mL. Biannual screening results in 
about half the total number of screenings and number of false-positive screenings, and 
captures 95% of the cases that would have been caught with annual screenings.  Using 
age specific PSA levels reduces false positives by 13.7%, but reduces the percentage of 






5.3.1 Improving Biopsies 
 Each year, approximately one million prostate biopsies are performed in the United 
States (Welch et al. [19]). Studies have shown that the standard sextant transrectal ultra-
sound-guided needle biopsy has a false negative diagnosis rate over 20% (Bankhead [3], 
Rabbani et al. [15]). Since the sensitivity of the standard biopsy is less than 80%, multiple 
biopsies may be needed to confirm prostate cancer. A biopsy is a painful, invasive proce-
dure that has a risk of infection, with 4% of patients developing an infection. Within 30 
days of a prostate biopsy, 6.9% of patients are admitted to the hospital (Loeb et al. [11]). 
To prevent the need for multiple biopsies, it is important to raise the accuracy of a biopsy. 
In the paper summarized, the authors tried to reduce the false negative rate by analyzing 
tumor locations and developing an optimal biopsy procedure. 
________________________________________________________________________ 
 
Sofer, Zeng, and Mun (42) developed optimal biopsy procedures for fixed numbers of 
needles. The authors used 301 surgically removed prostates to generate a 3D statistical 
distribution of cancer occurrence in the prostate. The prostate was divided into 48 zones 
and 6,000 subzones. A biopsy protocol specified the number of samples to take and the 
zones where the samples are taken. There is variability as to the exact position and angle 
the physician aligns the needle for the biopsy. The authors optimized the biopsy protocols 
to maximize the probability of detecting cancer. Using their 3D model, they estimated the 
detection rate for the current sextant method at 67.3%. The optimized detection rate for a 
biopsy with six needles confined to the posterior of the prostate was 78.8%. By increas-
ing the number of samples taken (to as high as 12), the authors showed that the detection 
rate could be as high as 85.5%. Biopsy procedures were developed for small and large 
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prostates that had better detection rates than the current sextant procedure. Further work 




5.3.2 Using an MRI to Detect Prostate Cancer 
Using an MRI to detect prostate cancer has been shown to reduce the number of 
men needing a biopsy by 51%, lower the false negative rate, and identify low-risk tumors 
(Thompson et al. [18]). Each year, unnecessary biopsies are estimated to cost $2 billion. 
An MRI could help prevent unnecessary biopsies, thereby reducing this cost (Ahmed et 
al. [1]). An MRI does not carry the same risks as a biopsy such as infection, bleeding at 
the biopsy site, and painful urination. Therefore, it seems reasonable to have an MRI and 
analyze the results before deciding to have a biopsy. In the four papers, the authors ana-
lyzed the MRI data of patients who had a tumor removed (the procedure is known as a 







Proton magnetic resonance spectroscopic imaging (MRSI) allows for the detection and 
quantification of biochemical markers within the prostate and has been shown to be an 
improvement over conventional magnetic resonance imaging (MRI). A 3D grid divides 
the prostate into voxels (a voxel is a volumetric element that serves as the unit of analy-
sis). Each voxel has its own spectra data from the MRSI. Matulewicz et al. (30) con-
structed an artificial neural network (ANN) model to automatically detect cancerous 
voxels in the prostate using MRSI data. MRSI data from 18 patients with positive biop-
sies for prostate cancer who later underwent radical prostatectomy was used to construct 
the model. A total of 5,308 voxels were used. One hundred forty eight voxels were la-
beled suspicious by an experienced spectroscopist, and 129 of the 148 voxels were con-
firmed to have cancer following the radical prostatectomy. Only voxels identified as can-
cerous by both histopathological maps and the spectroscopist were labeled as cancerous. 
The ANN model had input, hidden, and output layers, each with a single node. Two types 
of models were constructed. The first model had 256 variables based on the spectra. The 
second model added the percentage of the voxel that was in the peripheral zone, transi-
tion zone, periurethral region, and outside the prostate. Seventy percent of the data was 
used as a training set, 15% as a test set to prevent overtraining, and 15% as a validation 
set to measure performance. Since there is a random element in the generation of the 
ANN model, 100 models of each of the two types were applied to the same training and 
test sets. The model of each type that performed best on the test set was selected, and 
their performances on the validation set were compared. The AUC was .949 for model 1 
and .968 for model 2. The sensitivity on the validation set for model 1 was 50% (identify-
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ing 8 of 16 cancerous voxels) and 62.5% for model 2 (identifying 10 of 16 cancerous 
voxels). The specificity on the validation set for model 1 was 98.7% (identifying 770 of 
780 noncancerous voxels) and 99.0% for model 2 (identifying 772 of 780 noncancerous 
voxels). 
 
Anderson et al. (1) constructed logistic regression, nearest neighbor, and hybrid classifi-
ers to predict the risk of prostate cancer using MRI data. Multi-parametric images from 
dynamic contrast MRI, diffusion weighted MRI, and MRSI were used to generate fea-
tures (apparent diffusion coefficient, volume transfer constant, conventional average of 
T2 values, and spectroscopy scores) for 223 slices of prostates from 28 patients who had 
a radical prostatectomy (all of the prostate gland is removed). Gleason scores were as-
signed to each slice by an experienced radiologist. Leave-one-out cross-validation was 
used to separate the data into training and test sets. The models were trained to classify a 
slice as having a Gleason score between 0 and 4 or between 5 and 8. Logistic regression 
had an accuracy of 64.6% and an AUC of 0.66, and KNN had an accuracy of 74%. A 
hybrid approach was developed using linear regression with the number of cancerous 
neighbors from KNN. The hybrid approach had an accuracy of 77% and an AUC of 0.85. 
The hybrid approach identified the most aggressive cancers (Gleason score of 7 or 8) 
with an accuracy of 82% and an AUC of 0.86. 
 
Parfait et al. (33) constructed a support vector machine (SVM) and a multilayer percep-
tron to classify magnetic resonance spectra (MRS) of prostates as healthy or pathological. 
MRS data from 22 patients with positive biopsies for prostate cancer were used. There 
were a total of 2,464 spectra, with 1,062 spectra localized in the peripheral zone where 
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the majority of prostate cancer lesions are typically found. The peripheral zone spectra 
were manually classified as undetermined (286), healthy (636), or pathological (140). A 
variety of preprocessing algorithms could be applied including phase correction, baseline 
correction, and normalization. Nine combinations of preprocessing algorithms and classi-
fication method were compared. The best average performance using 5-fold cross valida-
tion was SVM with preprocessing using phase correction and baseline correction. This 
combination correctly classified 82.2% of undetermined, 94.3% of healthy, and 75.0% of 
pathological spectra. When restricted to the healthy and pathological classifications, 4.5% 
are misclassified with 83.6% sensitivity and 98.1% specificity.  
 
Kelm et al. (24) compared the use of quantitative and subspace feature extraction meth-
ods in linear and nonlinear machine learning classifiers for identifying prostate tumors 
with MRSI. A subspace method projects higher dimensional data onto a lower dimen-
sional subspace. Two quantitative feature extraction methods from the MRS literature 
and a new quantitative method were compared to four subspace feature extraction meth-
ods– principal components analysis (PCA), partial least squares (PLS), independent com-
ponent analysis (ICA), and nonnegative matrix factorization (NMF). These features were 
then used in either a linear classifier (logistic regression, generalized PLS, P-spline signal 
regression) or a nonlinear classifier (a random forest method that uses multiple decision 
trees, SVM, Gaussian processes). MRSI data from 24 patients were used to construct the 
models. Using published guidelines, 4,188 voxels were identified as healthy, undecided, 
or having a tumor. Cross-validation was performed by training on 23 patients and testing 
on the one remaining patient. None of the classifiers using quantification features outper-
formed a conventional ratio feature used by clinicians. Subspace methods improved the 
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performance of the classifiers, particularly the nonlinear classifiers. There was little dif-
ference among the performances of the four subspace methods. 
________________________________________________________________________ 
 
5.4 Prostate Cancer Treatment 
 There have been great advances in the treatment of prostate cancer in the past 30 
years. In 1985, the five-year survival rate was 75%; in 2006, it was 99.6% (SEER [17]). 
This increase is due to better treatments and earlier detection due to PSA screening. Sur-
gery (prostatectomy) has long been the primary form of treatment. Surgery carries a risk 
of pain, bleeding, infection, and death. There is also a chance of incontinence and erectile 
dysfunction.  
 Other treatment options include external beam radiation therapy, brachytherapy, and 
hormone therapy. Often treatments are used in tandem. For example, hormone therapy is 
used to shrink a tumor before radiation treatment. Because prostate cancer can be slow 
growing, a patient with a low risk cancer (e.g., Gleason Score ≤ 6, PSA < 10) may forgo 
immediate treatment and elect to monitor the progression of the cancer (known as active 
surveillance) through regular clinical exams, PSA testing, and surveillance biopsies.  
 Operations research models have been used to improve the delivery of treatment, 
compare treatment options, and help patients make treatment selections. 
5.4.1 Staging 
 Staging describes the classification of a cancer. This is important information when 
making a treatment decision. Prostate cancer can be slow growing, posing little risk to the 
life of some patients who have low risk based on clinical factors. Unnecessary treatment 
can result in worse health outcomes. Identifying a low-risk tumor can prevent unneces-
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sary treatment, while identifying a high-risk tumor can encourage a more aggressive 
treatment strategy. We summarize four papers that used data mining to identify the type 
or severity of the prostate cancer. 
________________________________________________________________________ 
Chandana, Leung, and Trpkov (4) constructed models with different combinations of au-
tomatic feature selection, sampling, and classifier to predict the stage of prostate cancer. 
Age, primary Gleason grade, secondary Gleason grade, PSA level, PSAD, DRE, TRUS, 
gland volume, positive biopsy core, total percent of cores involvement, and total cancer 
length in mm for 1,054 patients were used in the models. The prostate cancer was organ-
confined in 934 patients. There was an extra prostatic extension in 120 patients. The au-
thors generated 18 models with combinations of automatic feature selection (rough set 
features, PCA, GA-based continuous feature selection), sampling (under-sampling, syn-
thetic minority over-sampling technique (SMOTE), combined under-sampling and 
SMOTE), and classifier (SVM, KNN). SMOTE generated synthetic examples of extra 
prostatic extension patients, based on those in the data set, that were used in training. 
Dempster-Shafer fusion produced classification probabilities based on the classification 
probabilities from multiple classifiers and generated new classifiers from combinations of 
the 18 models. A GA identified the best set of classifiers for fusion. SVM with rough set 
for feature selection and under-sampling had the best performance of the 18 models with 
an AUC of .8376. A Dempster-Schafer fusion of four models had a total accuracy of 
90.1% and AUC of .8626.   
 
Kattan et al. (22) developed a statistical model to predict the probability that prostate 
cancer is indolent or in need of treatment. Kattan et al. used data from 1,022 patients 
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treated with retropubic radical prostatectomy. Patients with a PSA level greater than 20, 
Gleason grade four or five, greater than 50% biopsy cores positive, total cancer in biopsy 
greater than 20 mm, or total benign tissue in all cores less than 40 mm were excluded as 
being unlikely to have indolent cancer. This left 409 patients. The authors constructed 
three statistical models. The base model used PSA level, clinical stage, and primary and 
secondary biopsy Gleason grades. The medium model added percent of cores that were 
positive, and ultrasound prostate volume to the features of the base model. The full model 
replaced percent of cores that were positive with millimeters of cancerous and noncan-
cerous tissue. Bootstrapping was used to build the model and leave-one-out analysis was 
used to examine the predictive probabilities. The three models had AUC values of 0.64, 
0.74, and 0.79, respectively. The full model predicted too many indolent cancers (17% 
too high). The authors then translated their statistical models into nomograms. A nomo-
gram is a diagram that is used to calculate the probability of indolent cancer predicted by 
a specific model. 
 
Bone scan and CT imaging are commonly used to detect metastatic cancer by identifying 
bone metastases and enlarged lymph nodes, respectively. This is important in determin-
ing whether treatment with curative intent, such as surgery, is appropriate. Merdan et al. 
(31) and Risko et al. (35) developed logistic regression models based on data from more 
than 80% of community urology practices in Michigan to estimate the probability of a 
positive bone scan and a positive CT scan, respectively. The models were found to pro-
vide very good discrimination, based on estimates of AUC greater than 80%. Further-
more, the models were used to estimate efficiency and effectiveness of proposed guide-
lines for determining which patients should receive imaging tests. Criteria of Gleason 
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Score > 7 or PSA > 20 (for bone scan guidelines) and Gleason Score > 20, PSA > 20, 
Clinical State > T2a (for CT guidelines) were estimated to result in fewer than 1% of pa-
tients having missed positive results. Implementation of these guidelines was estimated to 
substantially reduce the number of negative imaging results and the total number of im-




5.4.2 Active Surveillance 
 Active surveillance has become a viable alternative to treatment. Active surveillance 
involves close observation of a patient with frequent visits to a doctor for a DRE, a PSA 
test, and possibly a biopsy. If there is a change in the tumor, a patient may need to decide 
on a treatment. Active surveillance allows a patient to delay treatment, thereby avoiding 
any side effects. The two papers summarized compared active surveillance to different 
treatment options. 
____________________________________________________________________________ 
Eldefrawy et al. (11) compared the cost of active surveillance to common treatment op-
tions (radical retropubic prostatectomy, robotic assisted radical prostatectomy, external 
beam radiation therapy, brachytherapy) for low-risk prostate cancer. Screening for pros-
tate cancer has led to an increase in diagnosis, particularly in early stage prostate cancer. 
Though 17% to 20% of men will be diagnosed with prostate cancer within their lifetime, 
only 3% will die from prostate cancer. Overtreatment can have a negative impact on pa-
tient quality of life due to treatment side effects such as erectile dysfunction and inconti-
nence. Active surveillance delays treatment, while having the patient undergo surveil-
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lance involving DRE, PSA testing, and biopsies. Procedure cost, professional fees, and 
inpatient costs were estimated based on Medicare reimbursement levels in the Miami area 
and the costs for a Miami area hospital for 2010. The authors estimated costs for treating 
low-risk prostate cancer over a 10-year period using a Markov model. The model consid-
ered the probabilities of various complications and recurrence from treatment options and 
the resulting costs. For example, each TRUS guided biopsy had a 1% chance of causing 
sepsis. Robotic assisted radical prostatectomy, the most commonly performed procedure 
for prostate cancer in the United States, had the second highest costs with a one-year cost 
of $17,824 and a 10-year cost of $22,762. Active surveillance had the lowest costs with a 
one-year cost of $1,154 and a 10-year cost of $13,116.  
 
Hayes et al. (21) used a simulation model to compare the QALYs for men with low-risk 
prostate cancer associated with active surveillance and initial treatment (brachytherapy, 
IMRT, radical prostatectomy). Active surveillance involves regular PSA testing, DRE, 
and biopsies. Active surveillance delays treatment until the prostate cancer progresses or 
the patient chooses to begin treatment. In the United States, 16% to 40% of newly diag-
nosed prostate cancer patients meet the criteria for active surveillance. The authors con-
structed a state transition model that they analyzed using Monte Carlo simulation. The 
model considered probabilities of side effects associated with brachytherapy, IMRT, and 
radical prostatectomy and with the disease in general. Probabilities were estimated based 
on a systematic literature review. Patient utilities were estimated by asking men not diag-
nosed with prostate cancer using the time-trade-off method. A hypothetical cohort of 65-
year-old men with newly diagnosed, clinically localized, low-risk prostate cancer was 
used as the patient population. Patients undergoing active surveillance had the best                                                         
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performance with 11.07 QALYs, compared to 10.57 QALYs for brachytherapy, 10.51 
QALYs for IMRT, and 10.23 QALYs for radical prostatectomy. Active surveillance had 
a higher risk of death from prostate cancer (11% compared to 9% for initial treatment). 
For those men undergoing active surveillance, 61% received treatment (brachytherapy, 
IMRT, radical prostatectomy) having been under active surveillance for a median of 8.5 
years.  
________________________________________________________________________ 
5.4.3 Hormone Therapy 
Hormone therapy can be used to shrink a cancerous tumor in the prostate before it 
is treated with radiation. Hormone therapy shrinks a tumor to a minimum size, after 
which the therapy loses effectiveness and the tumor starts growing. Less radiation needs 
to be delivered when a tumor is at its smallest, thereby reducing the side effects from the 






Lavieri et al. (25) used a dynamic Kalman filter model to predict when to begin radiation 
therapy. A Kalman filter is a recursive procedure that computes the optimal estimator of 
the state vector at each time period based on a series of noisy measurements. Since it is 
believed that the PSA level is lowest at the same time that the tumor’s size is at a mini-
mum, PSA level is used in lieu of tumor size. PSA level over time is modeled using a log 
quadratic curve, which has an average R
2
 of 0.9 for the 163 patients in the study. The au-
thors estimated the prior distribution of the curve parameters, then the distribution of the 
estimated time of the nadir.  A Kalman filter is used to update the estimates of the curve 
parameters. Finally, clustering was used to identify subgroups of patients with similar 
responses to hormone therapy. Protocol in British Columbia required that radiation thera-
py begin if the PSA level started to rise, if after four months the PSA level was below 
0.05 ng/mL, or eight months after beginning the therapy. Four new policies were pro-
posed that used the predictive model to determine if the nadir had a threshold probability 
of being reached within a fixed time period of PSA tests. Two of these policies outper-
formed the current policy; beginning treatment if the nadir is predicted to occur before 
the next PSA test or beginning treatment if the nadir is likely to occur within one month 
of the next PSA test. The mean absolute difference between the time of the nadir to the 
beginning of radiation therapy is 45 days for the current policy, but only 29 or 36 days for 





 Brachytherapy places radioactive seeds inside the prostate. The placement of the 
seeds affects the amount of radiation received by the tumor and other parts of the pros-
tate. When developing a treatment plan, the objective is to deliver an appropriate amount 
of radiation to the tumor and to the tissue identified as at risk of cancer, while sparing 
healthy tissue. Brachytherapy carries risks including urinary problems and erectile dys-
function. We summarize five papers that used mathematical models to optimize the 
placement of the seeds and needles and analyzed the risks of underestimating the Gleason 
score when treating with brachytherapy. 
________________________________________________________________________ 
Ferrari et al. (15) proposed a mathematical model that allowed for the simultaneous opti-
mization of seeds and needles in brachytherapy planning. The model took into account 
the prostate, urethra, rectum, and bladder. The volume was divided into discrete points 
where the radioactive seeds could be placed. Several quality metrics were used including 
the percentage of each tissue type receiving given dose levels, dose non-uniformity ratio, 
and percent of treatment volume achieving the prescribed dose. The dose for each point 
was calculated based on the sum of the radiation received from the seeds (inversely relat-
ed to the distance from the seed). Each seed is delivered by a needle and the needle can 
only deliver a finite number of seeds in a straight line that meet certain spacing criteria. 
The model minimized the number of needles and seeds, while maximizing the percentage 
of treatment volume above the prescribed dose and healthy tissue below a certain dose 
threshold. The authors developed a genetic algorithm to find good solutions to the math-
ematical model. The GA used a two-dimensional chromosome of integers that corre-
sponded to the seed placement and needles. The GA was used to develop plans for 11 test 
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patients. The authors established criteria for acceptable plan performance based on how 
well the plan matched the prescribed dose. The GA took an average of 20 minutes and 
found acceptable solutions in 10 of 11 cases. 
 
Lee and Zaider (28) devised optimization models and computational techniques for real-
time intraoperative 3D treatment planning in brachytherapy. Traditionally, treatment 
plans had been constructed several days or weeks prior to the implantation of the radioac-
tive seeds, following an ultrasound or computerized tomography scan of the prostate. The 
manual construction of a treatment plan is a lengthy process and can take several itera-
tions, and the images used to construct the treatment plan are often different from the im-
ages obtained when it is time to insert the seeds. This is in part because the prostate vol-
ume measured at the first imaging is often different from the volume observed in the op-
erating room. Discrepancies between the original imaging and the imaging during im-
plantation can increase the chance of undesirable side effects. Lee and Zaider formulated 
a mixed integer program (MIP) to optimize the placement of the seeds throughout the 
prostate. Constraints included dosimetric constraints for the tumor and critical structures. 
Constraints desired by the physicians, such as limiting the number of seeds, can also be 
included. In order to solve the MIP in real time, various techniques, including matrix re-
duction and a branch-and-cut environment, were used. The resulting plans delivered the 
prescribed dose to 98% of the prostate, reduced the number of seeds implanted by 20-
30%, and reduced urethra dose by 23-28% compared to other computerized techniques.  
 
Cambio et al. (3) used the probability of each outcome and the cost of each decision to 
assess the cost-benefit and outcome of recommending brachytherapy to men with a pros-
123 
 
tate biopsy Gleason score of six. The Gleason score from a sextant biopsy agrees with the 
Gleason score from a prostatectomy 46% to 63% of the time. An extended core biopsy 
(10 or more cores) agrees 76% of the time. A Gleason score of six is considered low risk 
of biochemical recurrence of prostate cancer, while seven is considered intermediate risk. 
Brachytherapy is considered an appropriate standalone treatment for a patient with a 
Gleason score six or lower, though it is not recommended by itself for a patient with a 
Gleason score of seven or higher. The authors estimated the treatment cost and quality of 
life changes of brachytherapy from previous research. A group of 60-year old patients 
with a prostate biopsy Gleason score of six were used for the analysis. Patients either had 
a true Gleason score of six or they had been undergraded and had a Gleason score of ei-
ther seven or eight to 10. Depending on the true state of the cancer, there were different 
probabilities that brachytherapy would successfully prevent biochemical failure (a rise in 
PSA levels after treatment considered to signal the recurrence of prostate cancer) within 
five years. A variety of biopsy accuracies were evaluated. For example, raising the 
agreement of the biopsy and prostatectomy Gleason score from 60% to 80% reduced av-
erage costs of treatment and recurrence from $63,780 to $62,929 per patient.   
 
Fu, Yu, and Liu (16) developed a genetic algorithm for planning of prostate brachythera-
py prior to the beginning of surgery, and replanning after some of the radioactive seeds 
have been placed. During brachytherapy surgery, needles can be deflected, changing the 
placement of radioactive seeds. Dynamic intraoperative treatment planning adjusts the 
placement of the remaining seeds based on the actual placement of the seeds already in-
serted into the prostate. The authors developed a genetic algorithm that first optimized the 
needle pattern (assuming one of a few seed spacing rules) and then optimized the seed 
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spacing. An original plan was constructed for a patient. Needles were randomly deflect-
ed, and seeds delivered as planned along the deflected needle. After one-quarter of the 
needles were delivered, the actual positions were known through imaging, and a new plan 
was constructed. After one-third of the needles in the second plan were delivered, a third 
plan was constructed. After one-half of the needles in the third plan were delivered, a 
fourth plan was constructed. After all the needles in the fourth plan were delivered, a fifth 
plan was constructed to ensure the tumor had received the necessary radiation. The quali-
ty of the reoptimized plans was compared to the original plan based on the number of 
seeds used, maximum urethral dose, and maximum rectal dose. The performance was 
based on three simulated runs for each of 10 patients using two different types of radioac-
tive seeds, iodine-125 with a prescription dose of 145GY and palladium-103 with a pre-
scription dose of 115Gy. Reoptimization led to a 10% to 20% increase in the number of 
seeds used, depending on the type of seed used. The deflections led to a 17% to 28% in-
crease in maximum urethral dose and 16% to 42% increase in maximum rectal dose, de-
pending on the type of seed.   
 
Lee and Zaider (27) formulated a mixed integer program (MIP) to optimize the place-
ment of the seeds throughout the prostate. A grid is placed over the potential seed loca-
tions in the prostate and binary variables were used to indicate whether a seed is placed at 
each location. The seed locations contribute to the radiation dosage at every point, and 
constraints include upper and lower bounds of radiation dosage at each point. Since it is 
not always possible to simultaneously meet all dose constraints two models are construct-
ed that either maximize the number of points meeting these constraints or minimize the 
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weighted sum of the deviations from the dose bounds. Constraints included dosimetric 
constraints for the tumor and critical structures. Constraints desired by the physicians, 
such as limiting the number of seeds, can also be included. Computational strategies in-
cluded matrix reduction, perturbation, and a penalty-based adaptive primal heuristic pro-
cedure. The MIP solver was able to solve sample problems within 15 CPU minutes and 
improve over the computer aided planning methods available. The MIP solver improved 
by using fewer seeds and needles, and providing better coverage and conformity. 
_______________________________________________________________________ 
 
5.4.5 Patient Choice 
 Men who receive an early prostate cancer diagnosis and are aggressively treated have 
a higher survival rate than those diagnosed with later stages of the disease. However, 
there is concern that screening can lead to unnecessary treatment, particularly for men 
with low-risk disease. When deciding on the best treatment for prostate cancer, a patient 
needs to consider two key factors: (1) the risk of prostate cancer progression and mortali-
ty and (2) the potential side effects of the various treatment options. We summarize three 
papers that developed models to help a patient select a course of treatment.  
  
___________________________________________________________________________ 
Simon (41) constructed a multiattribute utility model to help a patient consider five 
treatment alternatives: surgery (radical prostatectomy), external radiation, seed radiation, 
dual radiation, and no treatment. In the first part of the model, the life expectancy of a 
patient and the probability of death from prostate cancer were determined. The probabili-
ties of three side effects (impotence, incontinence, toxicity) that depend on the type of 
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treatment and factors specific to a patient were developed. In the second part of the mod-
el, a patient’s preferences were analyzed. For the three side effects, a patient needed to 
determine what percentage of remaining life he would be willing to forego to avoid a par-
ticular side effect (this is known as the emotional weight). Simon expressed the possibil-
ity of each side effect in terms of a reduction in life span. For a patient, a life score was 
developed that took into account the length and quality of life. It provided a patient with a 
weighted average utility for a specific treatment. For example, a life score of 95 for seed 
radiation would be preferred to a life score of 85 for surgery. Simon ran the model on 
different patient profiles and found some interesting results. Younger men who did not 
have an aversion to side effects had the highest life score for surgery. Older men had high 
life scores for treatments that were less aggressive than surgery. One result was contro-
versial: external radiation was used too often. Simon implemented a web-based version 
of this model that had an average of 400 hits per week in 2007. 
 
Liberatore et al. (29) developed a decision counseling method, based on the Analytic Hi-
erarchy Process (AHP), to help men make informed decisions about whether to screen for 
prostate cancer. AHP is a technique for analyzing complex decisions that takes into ac-
count the factors affecting the final decision. As part of a randomized controlled trial, the 
authors scheduled sessions for 129 men with a trained health educator to discuss prostate 
cancer screening. They used AHP to process a participant’s three top decision factors as 
identified by the participant during the session and to generate a preference score that 
reflected a participant’s preference to screen. The score was computed during the session 
using a calculator and was then given to the participant prior to the scheduling decision. 
The preference score was a statistically significant predictor of a participant’s decision to 
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schedule a screening exam. An analysis of the preference score showed affective decision 
factors (emotional factors), such as fear of getting cancer, were the most influential in a 
patient’s decision to be screened. Liberatore et al. concluded that AHP was successful in 
eliciting decision factors. They supported its implementation as part of decision counsel-
ing in the future. 
 
Chapman et al. (5) constructed a multi-attribute utility (MAU) model to examine the 
trade-offs between different treatment options for prostate cancer patients, with the goal 
of aiding patients in making treatment decisions. The authors considered five health at-
tributes that can be affected by patient treatment: pain, mood, sexual function, bladder 
and bowel function, and fatigue and energy. Their study had 57 patients from two Chica-
go Veterans Administration health clinics with either localized or metastasized prostate 
cancer. The patients’ preferences were measured using time trade off (TTO) judgments. 
The participants were asked how many years of full health were equivalent to 10 years in 
one of three levels for each health attribute. The patients then divided 100 points between 
the five health attributes to indicate their relative importance. Patients tended to place the 
most weight on pain followed by bladder and bowel function. The MAU model was 
compared to a global TTO preference assessment. The result of the comparison indicated 








 There are many forms of treatment available for prostate cancer.  Younger patients, 
who are healthy, are often encouraged to receive a radical prostatectomy. Older patients 
who are not good candidates for surgery are more often steered away from a radical pros-
tatectomy towards other forms of treatment such as external beam radiation therapy or 
brachytherapy. Regardless of the treatment selected there is the potential for recurrence 
following treatment.   
 If a patient’s PSA level rises above 0.1 ng per mL following a radical prostatectomy, 
the patient is considered to be at risk that his cancer persists. According to Catalona [5], 
the five-year probability of nonprogression after a radical retropubic prostatectomy for 
prostate cancer is 78%. We summarize seven papers that used data mining to identify 
patients at risk of prostate cancer recurrence. 
________________________________________________________________________ 
Dancea et al. (7) developed a support vector machine (SVM) model to divide patients 
into risk classes prior to a radical prostatectomy to aid in surgical decisions. They used a 
data set with 14 medical attributes for 399 patients: classification of malignant tumors, 
Gleason score, presence of median endo-vesical lobe, prostate volume, pre-operative 
PSA level, international index of erectile function, quality of life, abort operation, surgery 
technique, nerve sparing, surgery time, postoperatory hospital time, complications, and 
risk class. They trained their SVM model on 369 patients and tested on 30.The SVM 





Shariat et al. (40) reviewed the literature to compare nomograms, risk groupings, artifi-
cial neural networks, probability tables, and regression trees to determine their effective-
ness in predicting the risk of cancer recurrence. The published studies evaluated models 
on predictive accuracy, performance characteristics according to risk level, generalizabil-
ity, and level of complexity. The studies that were examined by the authors applied nom-
ograms and another model to a common external data set with known patient outcomes. 
Nomograms had superior predictive accuracy to risk groupings and probability tables. 
Regression trees constructed with CART analyses were easy to use and offered greater 
model-fitting flexibility than nomograms. In a head-to-head study, predictive accuracy 
was 70% for CART models and 84% for nomograms. ANNs have a high level of com-
plexity and are typically used as a black box method, but they can fit very complex pat-
terns.  In a study that applied nomograms and ANNs to an external data set, predictive 
accuracy was 70.6% and 67%, respectively.  
 
Androgen deprivation therapy is a common treatment for recurrent prostate cancer, but 
androgen-independent prostate cancer will eventually develop. NOXA and PUMA are 
two proteins whose presence may affect prostate cancer recurrence. Diallo et al. (8) gen-
erated recursive partitioning and regression tree (RPART) models with NOXA and 
PUMA to predict biochemical recurrence in prostate cancer patients. RPART models use 
a two-stage procedure to produce binary decision trees. The study had 43 patients with 
healthy prostate tissues, 62 patients presenting primary prostate cancer tissues, and 30 
patients with hormone-refractory prostate cancer. The authors constructed RPART mod-
els using NOXA and/or PUMA with combinations of preoperative PSA level, Gleason 
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score, pathologic stage, and resection margin status (the presence of cancer in the surgical 
margin that surrounded the designated tumor removed during the radical prostatectomy). 
The RPART model with the best performance was based on NOXA, PUMA, and the re-
section margin status. Nine of the top 10 models included NOXA to predict biochemical 
recurrence, while only three of the top 10 included PUMA. 
 
Biochemical failure-free survival (bFFS) refers to the probability that a patient’s PSA 
level does not rise for three consecutive tests following external beam radiotherapy for 
prostate cancer. If a patient’s PSA level rises for three consecutive tests following treat-
ment, this is a strong indicator of recurrent cancer. In order to determine a patient’s risk 
of relapse, Churilov et al. (6) applied clustering techniques to a set of post-treatment pa-
tients who had received external beam radiation therapy. The data set had Gleason score, 
tumor stage, PSA level at diagnosis, and age for 258 patients treated at the William Buck-
land Radiotherapy Center (WBRC) in Melbourne, Australia. The PSA level of each pa-
tient was taken at three-month intervals for the first year following the start of treatment, 
six-month intervals the next year, and then annually. Churilov et al. applied an optimiza-
tion algorithm for clustering based on earlier work. The clustering algorithm grouped the 
patients into 10 clusters. WBRC used a rule-based method with seven clusters. In each 
cluster, a patient was identified as low, intermediate, or high risk of having a biochemical 
failure in the five years following treatment. The WBRC method assigned 51.2% of all 
patients to an intermediate-risk category and 8.2% to a low-risk category. The clustering 
algorithm developed by Churilov et al. assigned 26% to low risk and 34% to intermediate 
risk, while maintaining a similar probability of bFFS for the categories as the WBRC 
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method. Those defined as low-risk by the clustering method had a 71.6% of five-year 
bFFS, compared to 76.2% for those classified by the WBRC method. Patient’s classified 
as intermediate-risk had a 53.1% and a 53.4% five-year bFFS for the clustering method 
and WBRC method, respectively. Churilov et al. improved the classification of patient’s 
risk, allowing doctors to make better decisions regarding post-treatment care. 
 
Seker et al. (38) constructed a Fuzzy K-Nearest Neighbors (FK-NN) classifier to predict 
the outcome of prostate cancer treatments for patients. Data from 41 men with histologi-
cally proven prostate cancer was used to construct FK-NN, linear regression, and artifi-
cial neural network models. Four conventional indicators of prostate cancer (tumor stage, 
skeletal metastasis, Gleason score, serum PSA level) and two experimental indicators 
(p53 immunostaining, bcl-2 immunostaining) were used to predict a patient’s response to 
hormonal treatment, radical surgery, or observation. Response to treatment was classified 
as either having no response to any type of treatment, complete response to treatment (no 
tumor progression for patients undergoing observation), or relapse following successful 
start (tumor progression for patients undergoing observation). Each model was trained 
using a leave-one-out method. Each model achieved a best predictive accuracy using a 
different subset of the indicators. Serum PSA and treatment type were the best indicators 
of patient outcome. The logistic regression model had a predictive accuracy of 41.46%. 
The artificial neural network model had a predictive accuracy of 53.66%. The FK-NN 
model had a predictive accuracy of 60.98% if the number of nearest neighbors was set to 




Seker et al. (39) extended their work by constructing a hybrid neuro-fuzzy rule-based 
system to predict the treatment outcome of a prostate cancer patient. A set of rules was 
generated to determine the classification of a patient. Each rule had a premise (a set of 
variables and conditions on which the rule was based) and a consequence (the classifica-
tion based on the premise). A neural network computed the parameters of the premise for 
each rule. Singular value decomposition selected the most and least important rules gen-
erated by using a k-means clustering method. The hybrid approach achieved a predictive 
accuracy of 63.42%. 
 
Kattan, Wheeler, and Scardino (23) developed a nomogram to predict the progression of 
prostate cancer in men treated with radical prostatectomy. Pretreatment PSA level, 
Gleason sum from the surgical specimen, prostatic capsular invasion (the presence of 
cancer cells in the capsule around the tumor), surgical margin status (the presence of can-
cer cells in the expected healthy tissue removed with the tumor), seminal vesicle invasion 
(the presence of cancer cells in muscular wall of the seminal vesicle), and lymph node 
status (the presence of cancer cells in the lymph nodes) for 996 men who underwent radi-
cal prostatectomy were used in the development and testing of the nomogram. Progres-
sion of prostate cancer was defined as PSA levels rising to 0.4 ng/ml or higher, a second 
PSA test that was higher than the first by any amount, or treatment with radiation or hor-
mone therapy within seven years of surgery. The nomogram had an AUC of .88, imply-
ing that for 88% of pairs of patients, the patient with the larger score will relapse first. If 
variables whose values were known only after the radical prostatectomy were removed, 





 With an aging population and a current expenditure of $11.8 billion for prostate can-
cer treatment in the United States (SEER [17]), it is important to understand where mon-
ey is being spent and what costs are likely to be in the future. Since many of those affect-
ed by prostate cancer are above the age of 65, Medicare pays for much of the screening 
and treatment. Accurately predicting future Medicare expenditures is important in long-
term planning. The two papers that are summarized explored the financial costs of pros-
tate cancer with one paper examining the costs prior to treatment and the other predicting 
future Medicare costs. 
________________________________________________________________________ 
 
Ekwueme, Stroud, and Chen (10) conducted a systematic review of published cost data 
for prostate cancer treatment in the United States and other industrialized countries, and 
then performed a statistical analysis of the data. The authors identified 262 articles pub-
lished between 1980 and 2003 whose title or abstract implied cost information on pros-
tate cancer treatment. From these, 28 (15 from the United States and 13 from other indus-
trialized countries) were available in full text, written in English, contained original re-
source cost data, and included screening, diagnosing, and staging costs. All costs were 
converted to 2003 U.S. dollars using the consumer price index (for the country of origin) 
and exchange rates. A weighted mean for the cost per man screened was taken, weighted 
by the number of men screened in each study. A Monte Carlo simulation method was 
used to determine uncertainty in the pooled resource costs. For the United States, the cost  
for PSA screening was $37.23 ($30.92 internationally) and DRE was $31.77 ($33.54 in-
ternationally). In the United States, costs have decreased for biopsies and PSA screening, 
while they have increased for clinical staging, pathologic or histologic analysis, TRUS, 
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urology consultation, and DRE. Internationally, resource costs associated with biopsies, 
PSA screening, pathologic or histologic analysis, TRUS, urology consultation, and DRE 
have decreased over time (over the course of one or more of the published studies). 
 
Penberthy et al. (34) analyzed the factors that predict Medicare expenditures in patients 
with breast, colorectal, lung, or prostate cancer. The authors combined data from the Vir-
ginia Cancer Registry, Medicare Provider Analysis and Review files, Medicare Automat-
ed Data Retrieval System, Medicare Health Insurance Master file, Medicare Annual De-
mographic files, Area Resource File, and 1990 Census Data for Zip Code Level infor-
mation. Expenditures were analyzed for one year following diagnosis, with cost being 
defined as the amount the Health Care Financing Administration reimbursed the health 
care provider. The data set had 1,952 breast, 2,563 colorectal, 3,331 lung, and 3,179 pros-
tate cancer patients. Treatments for prostate cancer were categorized as definitive surgery 
(287 patients), nonsurgical treatment (1,827 patients), surgery plus nonsurgical therapy 
(70 patients), and no treatment (995 patients). A two-stage least squares analysis was per-
formed to predict costs. The R squared value for prostate cancer was 0.38. The mean cost 
for prostate cancers was $14,361 for Virginia (1985-1988). Treatments that involved sur-
gery tended to cost more as did treatment for patients with any comorbidity. Predicted 
cost increased with income of the patient.  Patients who did not survive one year follow-










 Over the past 15 years, OR models and methods have been applied to diverse prob-
lems in the screening, detection, and treatment of prostate cancer. The results of these 
efforts have been impactful and important.  
 We expect that the use of OR will grow significantly in the next decade, not only in 
prostate cancer research, but also in more general research on healthcare problems. We 
hope that our bibliography and the attendant annotations will serve as a useful guidepost 





IMRT would not be possible as a treatment without the use of operations research 
techniques such as mixed integer programming and simulated annealing. IMRT has 
a three stage treatment planning process: identification of the tumor and organs at 
risk, selection of beam angles for delivery of radiation, and optimization of radiation 
delivery from those angles. Without methods to optimize the delivery of radiation to 
each of the hundreds of pixels from each angle, IMRT would not be able to reduce 
the amount of radiation being delivered to the healthy tissue of patients because of 
the size and complexity involved in planning. These patients would suffer more 
acute side effects from their treatment due to damage to their organs from radiation 
and they would have greater long term risk of developing new tumors. But the op-
timization of treatment planning for IMRT is incomplete, because most institutions 
still manually choose beam angles. By creating a decision support tool to aid in the 
selection of beam angle sets, we have found better solutions in a fifth of the time of 
traditional search. By using machine learning models trained on previously evaluat-
ed beam angle plans, we were able to sort potential beam angle plans, without the 
time intensive step of fully evaluating them we sort in seconds a list that would take 
almost a day to evaluate. Evaluating just the top three plans from a list sorted using 
k-nearest neighbors yielded better results than evaluating 15 plans from an unsorted 
list. All machine learning models had significantly better results than unsorted lists, 
allowing for treatment planners to find better plans faster. Decision support tools of 
this manner provide an intermediary step allowing treatment planners to still play a 
role in beam angle selection by suggesting potential beam angle lists. Such an in-
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termediary step, while perhaps not strictly necessary, could help the transition to 
completely automated beam angle optimization procedures. 
Next, we created a tool that searches all potential beam angles. This tool has the 
ability to find even better solutions than those proposed by the treatment planner. 
We used the models developed by the machine learning algorithms as the fitness 
functions for a genetic algorithm that searched the space of feasible beam angle sets. 
We incorporated patient tumor geometry into our machine learning models, both 
improving performance and increasing the applicability to new patients without ne-
cessitating any time intensive evaluation of multiple treatment plans. Our method 
was able to improve upon the best known solutions by more than 2% and yet still 
run in about six minutes. Our genetic algorithm works in a fraction of the time it 
takes to evaluate a single beam angle set. We are not only saving the time a radia-
tion oncologist would spend planning, but we are improving the quality of the 
treatment plans being generated.  
In addition to our work improving the quality of the treatment plans for radiation 
therapy, we used simulation to aid in the design of proton therapy treatment centers 
and decrease patient wait times. Given the large capital investments and the unique 
interactions between system resources, it is crucial that the facility is efficiently de-
signed and patients are scheduled intelligently. Our simulation showed the decreas-
ing returns of adding additional gantry rooms, from a 26% increase in throughput 
for a fourth gantry room, to a 14% increase for the fifth, a 6% increase for the sixth, 
and no increase for further gantry rooms. The cyclotron is fully utilized at six gantry 
rooms, identifying the cyclotron as the limiting resource of the facility. We generat-
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ed schedules that by ordering patients using treatment plans, reduced the average 
time spent waiting by over 30%, reduced the variance of the total wait time by 30%, 
and reduced the number of patients waiting longer than 10 minutes by 80%. As an 
outpatient procedure, patient’s arrival time is highly uncertain. Outpatients have 
high probabilities of both absenteeism and tardiness. Such uncertainty increases pa-
tient wait times of the most precise schedules by up to 60%. In the presence of such 
uncertainty, simpler schedules such as block scheduling become competitive. Even 
using block schedules, it is still important to schedule patients based on treatment 
plan. When using block schedules, the even distribution of treatment plans through 
the day reduces patient wait time by 20%. Furthermore, simulation can prepare 
planners for patients with special needs and for equipment failures. 
Finally, we have analyzed the impact of operations management on the treatment 
of prostate cancer. Operations management techniques have been applied to every 
stage of prostate cancer, from detection to postoperative monitoring. Machine learn-
ing methods have been applied to improve detection using both PSA and MRI. 
Large scale simulations have had an impact on policies surrounding PSA screening. 
Integer and linear programs have been used to improve the dose distribution of radi-
ation during brachytherapy. Markov models have been used to aid in treatment 
choice decisions. This research has impacted both the recommendations of doctors 
and the design of the way they treat their patients. It has impacted policy and budg-
ets.  
Operations management has already had a significant impact on the delivery of 
healthcare in the United States. Its importance, in improving the efficacy and effi-
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ciency of healthcare treatment, will continue to grow as demand for healthcare 
grows, with more people having access to healthcare, and advanced new treatments 
are developed. Along with the efficient delivery and utilization of medical re-
sources, techniques that can harness the vast amounts of data being generated will 
play an increasingly important role. Using machine learning to find patterns in the 
treatments and outcomes of patients has the potential to quickly find adverse drug 
interactions, identify the best treatments for patients, identify risk factors in disease 
development, and to search for patterns in patient outcomes. As new treatments are 
developed for patients, simulation becomes important for determining throughput 
and designing workflow. Simulation can be used, prior to building new facilities, to 
aid in the intelligent design of schedules for patients, nurses, and doctors. Simula-
tion can help insure the efficient use of equipment, which might otherwise become a 
bottleneck in the system. We have applied our models from system level decisions, 
about facility design and patient scheduling, to treatment level decisions, optimizing 
the radiation delivery to minimize damage to healthy tissue. We have seen how op-
erations research models have affected the treatment of prostate cancer. The poten-
tial of operation research to improve healthcare delivery is only limited by 
healthcare practitioners’ willingness to implement recommended changes. In order 
to have the greatest impact, researchers need to work to communicate not only the 
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